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ABSTRACT 
Background:  Clinical and research experience indicates that a high HIV prevalence setting 
will have a high occurrence of conditions that are associated with HIV.  These conditions are 
not always infectious in nature.  General physiological pain, neuropathic pain (NeuP) and 
anxiety disorders are conditions that have a high prevalence in people living with HIV 
(PLWHIV).  There is however, a literature gap on the prevalence of these conditions in 
Nkomazi Sub-district in South Africa’s Mpumalanga Province. This study therefore aimed to 
serve as a baseline study for the determination of the prevalence of anxiety disorders and 
neuropathic pain amongst PLWHIV who attended Highly Active Antiretroviral Therapy 
(HAART) clinics in Nkomazi Sub-district. 
Aim of the study: To determine the prevalence of anxiety disorders among PLWHIV with 
neuropathic pain who attended HAART clinics in Nkomazi sub-district. 
Objectives of the study: 1) To determine the prevalence of Neuropathic Pain among patients 
attending HIV clinics in Nkomazi Health District; 2) To determine the prevalence of Anxiety 
disorders among PLWHIV experiencing neuropathic pain who attended HIV clinics in 
Nkomazi sub-district. 3) To determine the Types of Anxiety Disorder among Nkomazi 
PLWHIV with NeuP who have one, or more anxiety disorders.  
Methods: The objectives were achieved through a cross-sectional study using an interviewer-
administered questionnaire. Three out of 34 facilities were sampled for the study and 
participants were recruited and interviewed for a month in April 2013. A total of 508 
participants were recruited. The questionnaire was adapted from the Structured Clinical 
Interview DSM IV Axis I Disorders (Clinicians’ Version) or SCID-CV and the DN4 
interview tool for neuropathic pain. The questionnaire also sourced demographic data from 
all participants. Age is summarised using non-parametric statistics. Categorical variables are 
summarised using percentages and a bar graph. The Chi-squared and the Fisher’s exact tests 
are used to compare binary categorical variables. The Prevalence Ratio is the relative 
measure of association used.  The p-value is set at ≤0.05 for statistical significance.  The 95% 
confidence interval (95 =% CI) depicts the precision of estimates.  Ethical and access 
approval were granted by the University of Cape Town Research Ethics Committee and the 
Mpumalanga Department of Health respectively. 
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Results: Participants were recruited at kaMhlushwa clinic (n = 203 or 39.96%; 95% CI: 35.67 
– 44.37), Naas clinic (n = 126 or 24.80%) and Mangweni clinic. There were more females
(77.56%; 95% CI: 73.68 – 81.12; n = 394) than males (22.44%; 95% CI: 18.88 – 26.32; n = 
114). Pain prevalence was 46.06%; 95% CI: 41.66 – 50.51 (n = 234).  The prevalence of 
neuropathic pain was 17.72%; 95% CI: 14.49 – 21.32 (n = 90) and that of anxiety disorders 
among those participants with Neuropathic pain was 80%; 95% CI: 70.25 – 87.69 (n = 72). 
Conclusion: This study confirmed the high prevalence of a complex disease burden in a high 
HIV prevalent Primary Care setting. The community has high prevalence of pain, anxiety 
disorders and neuropathic pain amongst PLWHIV patients on HAART.  
Keywords: Pain, Neuropathic Pain, Anxiety disorders, Nkomazi 
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1. INTRODUCTION
Both neuropathic pain and anxiety disorders are prevalent among people living with the
Human Immune deficiency Virus (PLWHIV). The introduction chapter sets the background for
this study which looks at the prevalence of anxiety disorders among people living with Human
Immune deficiency Virus (PLWHIV) and have neuropathic pain who attended clinics in
Nkomazi sub-district, Mpumalanga Province of South Africa (2013).
1.1 Nkomazi sub district 
Nkomazi is ranked third highest out of 17 sub-districts in Mpumalanga with ante-natal HIV 
prevalence of 47.3%, and 50% in the most affected sub-district in the province (2010).  While 
other areas in the province had a decline in ante-natal HIV prevalence between 2006 and 
2010, Nkomazi had an increase, 35.5% to 47.3%.  Compared to the national prevalence 
(29.4%, 2010), Mpumalanga had 35.1%1.  This paints a picture of the gravity of HIV infection 
in Nkomazi.  
1.2 Anxiety and Pain among PLWHIV 
Anxiety and distress often accompany diagnosis, and living with HIV2.  Short-lived fear 
benefits all vertebrates3, but has negative effects when prolonged2,3.  Pain, stress and HIV 
symptoms produce a complex picture in PLWHIV4.  Somatic symptoms of HIV provoke anxiety; 
eliciting pain and suffering5.  Doctors often under-estimate the feelings, fears, anxiety, pain 
and suffering experienced by PLWHIV; focussing on the disease at the expense of patient-
centeredness2.  Pain and anxiety are poorly recognized and sub-optimally treated2,4,5; with up 
to 84% of pain untreated although widespread among PLWHIV6-8.  Of all types of pain, 
neuropathic pain is the most difficult to diagnose and treat.    
HIV infection predisposes to anxiety and anxiety predisposes to infection6,7,9; with high 
anxiety levels increasing pain perception and pain increases anxiety6,7,9-11.  There is, thus, a bi-
directional relationship between HIV and anxiety13.   Poor educational status influences this 
relationship negatively12,13.  Traumatic events precede post-traumatic stress disorder (PTSD), 
generalized anxiety disorder (GAD) and panic disorder (PD), with or without HIV12.  Anxiety 
over-activates the sympathetic nervous system and the hypothalamus-pituitary-adrenal axis 
(HPA), both linked to immune organs14-16.  
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Pre-morbid anxiety or anxiety sensitivity increase catastrophic thinking10 and AIDS in the 
spouse worsens anxiety14.  However, in South Africa (RSA) there is little difference in levels of 
distress between PLWHIV and other chronic illnesses; and it seems the high prevalence of HIV 
in RSA give PLWHIV a sense of belonging15.  Anxiety in PLWHIV exacerbate disease 
progression; and PLWHIV who have anxiety disorders also struggle with symptoms and 
psychological effects of HIV17-22.  Anxiety disorders have notably escalated among PLWHIV 
while organic disorders like encephalitis and delirium have decreased12,13,23.       
1.3 Link between anxiety and pain 
PLWHIV experience pain and anxiety more than the general population2,8,10,24; with hyper-
vigilance triggering panic attacks, the basic units of anxiety disorders2,4,8,24.  Anxiety disorders 
and pain in PLWHIV form a vicious loop with overlapping brain mechanisms5-7,9.  Caucasians 
are more likely to report pain, while black patients report less pain despite having higher pain 
intensity5,6 and poor socio-economic status increases prevalence and intensity of pain and 
anxiety 5.  Pain intensity and experience are maximal if PD and PTSD are co-morbid, with PD 
the greater predictor of pain.  Pain and anxiety cause physiological arousal, with complex 
neuro-endocrine events releasing cytokines, which are counter-productive if prolonged12,13,22. 
Trauma increases sexual risk-taking; while anxiety plus mood disorders frequently co-occur in 
PLWHIV25-29.  Child abuse is known to predispose victims to promiscuity, substance use and 
PTSD; with negative outcomes and pre-morbid anxiety being constant, or worsening in 
PLWHIV30-33.  PLWHIV are likely to be of lower socio-economic status but those with obsessive 
compulsive disorder (OCD) may have higher educational levels32,34.  Worries about body 
image provoke anxiety among infected teens35.  Anxiety and pain in PLWHIV are independent 
of the bio-markers of the disease36-38.     
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1.4 Unique presentation of some Anxiety Disorders among PLWHIV. 
Interestingly for social anxiety disorder (SAD), OCD and specific phobias, the prevalence 
between PLWHIV and the general population are similar24.  Adjustment disorders are now 
less prevalent since the availability of HAART among indigent patients23.  Efavirenz and 
tenofovir are part of HAART but cause psychiatric morbidity among some PLWHIV22,23.  Up to 
2-4% of PLWHIV self-medicate with substances and are prone to substance use disorder,
alcohol being dominant24,27.  Hyper-vigilance and rumination about pain and negative 
outcomes maintains PD and PTSD10.    
1.5 Pain beyond the flesh 
Living with HIV is a primal threat with inappropriate flight/fight response and chronic 
physiological arousal3,8,10; resulting in psychological and physical symptoms in PLWHIV9,27. 
Despite HAART the threat of mortality still persists2, initiating and maintaining anxiety 
disorders24,27; with “harmless” anxiety symptoms and pain disrupting all the spheres of 
health: physical, mental, social and spiritual2,26,38,39.  Dame Cicely Saunders described this 
concept of total pain where pain outweighs the structural, physiological or biochemical 
damage26.   
1.6 Neuropathic pain and anxiety in PLWHIV 
Unlike the relationship between pain and depression in PLWHIV, less is known about the 
prevalence of anxiety disorders among PLWHIV with neuropathic pain.  HIV has a predilection 
for neural tissue causing distal symmetrical neuropathy (DSP), post-herpetic neuralgia, pain 
of central origin and mono-neuritis multiplex in PLWHIV36,39,41,42.  Neuropathic pain is most 
difficult to diagnose, complex to treat and complicates both HIV and HAART6,42.  Life 
prolongation with HAART has increased symptom burden with neuropathic pain inducing 
negative neural changes centrally22,36,38,44-51.  When pain experienced by PLWHIV is 
neuropathic the anxiety that accompanies the pain is likely to be more florid. 
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2. LITERATURE REVIEW
The introduction chapter described the importance of pain and anxiety disorders among
PLWHIV.  The research focuses on the prevalence of anxiety among PLWHIV with neuropathic
pain. This chapter critically appraises some work done on neuropathic pain and anxiety
disorders among PLWHIV.
2.1 Sources of literature 
A literature search was done in the following data bases:  EBSCO, Google Scholar, Psych Info, 
Science direct, CINHAL, MEDLINE, PUBMED, JSTOR and Medscape.  The following were the 
keywords used:  anxiety disorders, neuropathic pain, co-morbidity and HIV/AIDS.   
2.2 Anxiety disorders among PLWHIV 
2.2.1 Introduction 
The literature search targeted the anxiety disorders and pain, especially neuropathic pain, 
among people living with HIV/AIDS as a unique sub-population.  Neuropathic pain was 
targeted since it is one of the most difficult and frustrating pain syndromes to treat.  The 
anxiety disorders as a group of illnesses frequently co-occur with each other, other psychiatric 
disorders and other medical disorders including pain4,8-14,16,35.  Although Benton’s work (2010) 
looked at children and adolescents only, the issue of co-morbidity is similar to that in the adult 
population35.  The literature search mainly concentrated on the co-occurrence of the anxiety 
disorders with pain in people living with HIV/AIDS, but more specifically the literature 
searched looked at both anxiety disorders and neuropathic pain in this sub-population. 
As an introduction to the relevance of fear and anxiety among PLWHIV Casole et al (2011) and 
Baumann (2004) described these emotions in terms of their evolutionary values3,8.  Fear is an 
emotion that prepares man to fight, flee or freeze; irrespective of what elicits the fear.  Such 
a description is important considering that being infected and living with HIV evokes many 
fears and uncertainties (Gonzales et al, 2010)5.  Baumann reiterates the unpleasantness of 
anxiety, but also its importance, when it is acute8.  The usefulness of anxiety disappears when 
it becomes chronic and established, and there is impairment of functioning; one may then 
diagnose an anxiety disorder8,24.  Tuncay (2007) described how HIV puts immense pressure 
on a patient’s physique, psyche, sense of independence and sexuality2.   
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At the time of doing this literature review and obtaining approval of the research proposal by 
the University Ethics Committee, the Diagnostic and Statistical Manual Fifth edition (DSM V) 
was still being developed; therefore in this research the DSM IV or DSM IV Text Revision (DSM 
IV TR) is referred to (First et al)24.  In the topic on anxiety disorders Baumann (2004) described 
six major types of anxiety disorders.  These types were:  panic disorder (PD), post-traumatic 
stress disorder (PTSD), generalized anxiety disorder (GAD), obsessive compulsive disorder 
(OCD) and specific phobias8.  The Structured Clinical Interview for DSM IV Axis I disorders 
(SCID-I) (First et al, 1997)24, however, goes on to list some more types of anxiety disorders 
besides the ones mentioned above:  Anxiety disorders not otherwise specified (NOS), 
substance induced anxiety disorders, adjustment disorder, anxiety disorders due to 
generalized medical conditions and eating disorders are also included in the SCID-I24.  The 
DSM-IV TR also includes acute stress disorder (ASD) as another type of anxiety disorder8.   
2.2.2 Epidemiology of anxiety disorders among PLWHIV 
Tuncay (2007) in a review article highlighted how anxiety disorders are still prevalent among 
PLWHIV on HAART.  The fact that the emotional pain of being infected with the virus is 
compounded by anxiety is also mentioned in the same article2.  In their study of the 
relationship between pain, panic disorder and post-traumatic stress disorder among PLWHIV 
by Tsao et al (2004) noted that although anxiety disorders were frequently co-morbid with 
each other this co-occurrence did not have a multiplicative effect on the level of pain that 
PLWHIV would have if they had pain, except where PTSD and PD co-occur.  They noted that 
panic disorder was a stronger predictor of pain than post-traumatic stress disorder9.   
Catastrophic thinking which is quite frequent in panic disorder escalates anxiety symptoms 
both in PLWHIV and people without HIV infection but who do have pain and/or anxiety9. 
Notably, anxiety sensitivity is also high among PLWHIV with panic disorder and helps to 
maintain anxiety disorders, especially panic disorder5.  Interestingly pain in PLWHIV is both a 
trigger of panic disorder and pain is also a symptom of panic disorder.  The robust literature 
review of systematic reviews and good case-control studies by Tsao et al (2004) noted that 
cognitive bias which is a strong feature of PTSD also increases pain intensity and experience.  
The fact that avoidance is prominent in PTSD is enhanced by pain, physical deconditioning 
frequently follows avoidance which, in turn, increases pain intensity.  This partly points to 
how pain and anxiety are mutually maintained9.      
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2.2.3 Pathophysiology of anxiety disorders 
In their work on neurobiological basis of anxiety disorders Tsao et al (2004) reviewed other 
seminal articles that emphasized the overlapping mechanisms for anxiety and pain9.  Serchuck 
et al (2010) described the link among pain, stress, psychiatric disorders and reduced immune 
function; and immune dys-regulation is problematic in PLWHIV4.  In anxiety disorders 
interoceptive perception is affected by interactions between brain regions in the cortex, the 
brain stem centres and the limbic system.  The anterior cingulate cortex, the dorso-lateral and 
medial pre-frontal cortex are the cortical regions involved in this interaction3,9.  The 
periaqueductal grey (PAG) is a major brain stem region involved in the processing of pain and 
anxiety9.   
Unlike depression PLWHIV anxiety disorders among the same subpopulation has not been 
widely studied9,10,12.  Roy-Byrne et al (2008) and Gonzalez et al (2009) also acknowledged this 
fact but also that the association between pain and anxiety disorders is stronger than that 
between depression and pain10,12.  The work done by these co-authors was based on pain and 
anxiety among patients with other chronic medical conditions, not HIV/AIDS, though. 
Although the co-workers are well published in this field, this article was an opinion of experts. 
Pre-morbid anxiety among PLWHIV, illness anxiety and anxiety sensitivity (AS) cause people 
to respond to their illness with catastrophic thinking5,10,38.  This same group of experts noted 
in their paper the adaptive value of acute pain; but this value is lost once the pain becomes 
chronic10.  Based on their observation the contribution of anxiety and fear to the pain 
experience cannot be overemphasized9,10.  Campos et al also confirmed that prevalence of 
anxiety disorders among a Brazilian sub-population was higher than that for depression in the 
same group20.  They, however, did not use SCID-I as the tool for screening for anxiety 
disorders, instead they used HADS (Hospital Anxiety and Depression Scale) which is a rating 
scale as opposed to SCID-I which is a diagnostic tool.  The amplification of pain by anxiety in 
chronic medical conditions is well known and described as the effect of the mind on the body, 
and effect of the body on the mind9, 10.   
Serchuck et al (2010) and Brief et al (2004) reviewed articles of other experts on pain and 
anxiety; and described the possible potential pathways through which traumatic events 
negatively affected health outcomes leading to neurobiological changes4,30.  Traumatic 
exposure leads to increased risk-taking, neurochemical and physiological changes; and 
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negative psychological responses to trauma lead to immune suppression29,30.  The negative 
affect and negative emotions lead to neurochemical and physiological changes30.  Stressful 
events suppress immune cells and trauma suppresses immune function4,29,30.  PTSD and 
substance use disorder (SUD) are common in pre-morbid people who test negative for HIV 
but who do have the risk factors for HIV infection30.  Trauma increases psychological 
symptoms and somatization; and cumulative exposure to trauma eventually leads to poor 
self-care plus risk-taking.  Brief and co-workers summarised their review in this way:  trauma 
causes acute stress disorder, which progresses to PTSD in some patients, but not in all 
exposed to trauma.  PTSD leads to risky sexual behaviour and HIV infection in some people. 
Negative life events and mal-adaptive coping skills are predictors of worse outcome of the 
anxiety in PLWHIV according to Olley et al (2006)33.   
A new struggle in life ensues for some people living with HIV and who are clinically doing well 
on HAART.  For them their life-span is extended medically but this does not prepare them for 
the changes in relationship dynamics, work life and the retirement at the normal exit age 
according to Hinkin et al (2001)51.  Indeed the anticipation of living to up old age becomes a 
challenge in some of the greying PLWHIV13.  Hypothetically a pre-HAART patient might have 
come to terms with the possibility of premature death before initiation of HAART, but then 
initiation of treatment with HAART changes all this.    
2.2.4 Consequences of anxiety disorders 
Anxiety disorders among people living with HIV have their benefits and risks.  Worrying about 
the progression of the disease may help improve treatment adherence in some patients; 
while concerns about physical symptoms and signs may decrease adherence, well-being and 
immune function.  Worrying about toxicity of the drugs could also lead to reduced adherence 
to therapy.  Reduction in functioning of the immune system when there is an anxiety disorder 
has already been mentioned, so chronic anxiety worsens the viral immune suppression and 
counteracts the effects of HAART.  The basic characteristic of most anxiety disorders being 
the disruption and dys-regulation of the hypothalamus-pituitary-adrenal axis (HPA axis), the 
sympathetic and adrenal medullary system.  This disruption increases the levels of stress 
hormones, adrenaline and cortisol.  Disease progression follows persistently elevated levels 
of adrenaline and cortisol4,30. 
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PTSD among PLWHIV has been extensively studied18-20,28,30-34.  Gonzalez et al reiterated the 
significant relationship between psychologically traumatic events and PTSD, GAD and panic 
psychopathology12.  The DSM-IV states that diagnosis with a life-threatening illness qualifies 
as a traumatic event with a possibility of resulting in PTSD.  And PTSD that results from the 
diagnosis of HIV/AIDS ranges from 15% to 64% depending on the screening tool used. 
Negative emotions such as sadness, hopelessness, guilt, disappointment, blame, helplessness 
and despair make being diagnosed with HIV a psychologically distressing event.    Difficulty in 
assessing and defining traumatic events makes diagnosis of PTSD difficult in PLWHIV18.   
The complex life history of some, though not all, PLWHIV is discussed by Whetten et al (2008) 
in their review article19.  Importantly psychological trauma was found to be more prevalent 
among PLWHIV than among the general population.  Post-diagnosis abuse escalates in some 
PLWHIV and this increased the prevalence of anxiety and PTSD; stigma also increases risks of 
PTSD19.  In a case-controlled study, which had the disadvantage of a small number of 
participants, Junqueira et al (2008) observed that most of the anxiety symptoms among the 
PLWHIV studied were provoked by uncertainties about the eventual outcome of the infection. 
Fear of pain, physical decline and premature death as a result of infection with HIV all evoke 
anxiety symptoms26.   
Adewuya et al (2007) cautioned about the need to differentiate between the established 
anxiety disorders and “sub-syndromal symptoms of anxiety” which may follow being 
diagnosed with HIV infection.  Factors that contribute to psychiatric morbidity are:  pre-
existing psychiatric disorders, psychological reaction to a life-threatening illness, metabolic 
disturbances, side effects of medications and opportunistic infections28.  
A number of studies have observed that stigma is an underlying foundation for extreme 
emotional distress; and there is subsequent poor psychological functioning with resultant 
anxiety disorders in some patients12-14,,22,28,51.  Gonzalez et al (2009) observed that PLWHIV 
who had higher levels of mindfulness had significantly lower levels of anxiety and less 
catastrophic thinking.  Their study did not use the SCID for screening for anxiety disorders12.  
Nebhinani et al (2011) noted that stigmatization also enhances the bi-directional nature of 
the relationship between HIV and anxiety27.  
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Some other aspects of social anxiety disorder (SAD) like shyness and lack of assertiveness 
compromise safe sexual behaviour and practice.  PLWHA who have SAD and HIV-negative 
people with SAD are easily embarrassed about negotiating for safe sexual practice.  Mental 
disorders as mentioned in the article of Whetten et al (2008) do worsen disease progression19. 
Anxiety and HIV are the legendary egg and chicken scenario29,51.  This is explained by anxiety 
disorders leading to infection with HIV and living with HIV also leads to anxiety disorders51. 
The chaotic lifestyles lead by people with psychiatric morbidities lead to their low probability 
of practising safe sex.  Infection with HIV directly leads to some anxiety disorders and anxiety 
disorders predate infection with HIV in some people51.  Treatment with efavirenz has negative 
psychological consequences, while the protease inhibitors seem to have a favourable 
profile51.  In the article by Whetten et al (2008) it is mentioned that if dementia is excluded, 
older age is known to be generally protective against other neuro-psychiatric disorders until 
HIV enters the picture25.   
Benton (2010) discussed factors that threaten emotional health in HIV infection:  coping with 
pain in the body, worry about health, the disruption of social life, isolation, fear of disclosure, 
anger and worry about self-image35.  In their French Guiana study Nacher et al (2010) 
observed that patients on HAART had a higher rate of GAD than the PLWHIV but not on 
HAART22.  Their tentative explanation was similar to the transition points highlighted by Hinkin 
et al (2001)54.   
2.3 Neuropathic pain among PLWHIV 
There is a strong intimacy between HIV and the nervous system; the brain is always infected 
and the peripheral nervous system is usually affected36,41.  Attas (2002) cited articles that 
deliberated on the fact that the neuro-psychiatric complications of HIV are not dependent on 
biological markers of the disease36.  However, the severity of the neurological complications 
is predictive of mortality36.   
Peripheral neuropathies, post-herpetic neuralgia (PHN) and pain of central origin are some of 
the types of neuropathic pain in PLWHIV2.  Up to 1/3 of PLWHIV have distal symmetrical 
polyneuropathy (DSP).  In a review article authored by experts mainly from NeuroAIDS 
Research Programme Verma et al (2005) also noted that DSP was the most prevalent 
neuropathy among PLWHIV.  Despite this high prevalence neuropathy among PLWHIV 
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remains a problem that is underdiagnosed and undertreated; and pain is the most devastating 
symptom of DSP39.   
2.3.1 Definition of neuropathic pain 
The International Association for the Study of Pain (IASP) and the IASP special interest group 
(NeuPSIG) define neuropathic pain differently38,41-43.  The NeuPSIG defines neuropathic pain 
as “pain that arises as a consequence of a lesion or a disease affecting the somatosensory 
system” and by the time of doing the Nkomazi clinics study this was the most recent definition 
of neuropathic pain42,43.  Bouhassira elaborated on the new definition in depth in a review 
article “The Saga of the Clinical tool”43.  The older definition of neuropathic pain according to 
IASP was:  “pain initiated or caused by a primary lesion or dysfunction of the nervous 
system”41,42,43.  Both definitions, unfortunately do not take the quality of neuropathic pain 
into consideration43.  Even with a new definition of neuropathic pain, agreement by experts 
on a single universal diagnostic tool is still lacking52-56.  Work done by Kaki et al (2005) 
reviewed other articles which, in summary, warned clinicians about “over-simplifying a 
complex process” of dividing pain in to a purely neuropathic or nociceptive process.  These 
two extremes are best looked at as co-existing parts of the same spectrum57.     
2.3.2 Epidemiology of neuropathic pain 
According to an article by Verma et al (2005) up to 80% of pain in AIDS patients is 
undiagnosed39.  In an international Sub-Saharan, multi-centre study, Harding et al found that 
pain of all types among PLWHIV receiving HAART concurrently with palliative care up to 82.6% 
of the patients reported pain11.  The difference is that their study did not specifically look for 
neuropathic pain but sought pain of all types among their cohort of PLWHIV.  And previous 
systematic review by Verma et al (2004) had found the prevalence of pain in PLWHIV to be as 
high as 84%39,40.  Little has changed in the prevalence of pain with advances in treatment of 
the disease.  However, Hitchcock et al (2008) found a much lower prevalence (20.9%) of pain 
of predominantly neuropathic origin (POPNO) in pre-HAART patients in an urban academic 
setting in South Africa41.  Anxiety disorders that are co-morbid with neuropathic pain in 
PLWHIV are even less studied; Brief et al (2004) in a review article noted that physical 
symptoms, including pain in PLWHIV tend to be severe if there is PTSD30. 
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Neuropathic pain is underdiagnosed and even when diagnosed is usually undertreated 
according to two articles by Verma et al (2005)39 and Verma et al (2004)40.   Of all the 
neuropathic pain in PLWHIV distal symmetrical polyneuropathy (DSP) is the commonest and 
pain is its most devastating symptom among others39,41.  Among PLWHA neuropathic pain is 
most common among those with low albumin levels, intra-venous drug users, stavudine and 
didanosine (d-drugs) as part of HAART (d-drugs), those with very low CD4 counts, those with 
very high viral counts and the female gender39,41,46.  Miaskowski et al (2011) also reported on 
the other characteristics of pain in PLWHIV other than intensity.  They used Brief Pain 
Inventory and Pain Qualities Assessment Scale as the study instruments for holistic evaluation 
of pain in a longitudinal cohort of patients45.  Dorsey et al (2006) emphasized that the 
advantage of prolongation of life with HAART has added the burden of neuropathic pain47. 
2.3.3 Qualities of neuropathic pain 
Sensory descriptors of neuropathic pain include words that have been found to be universal 
across cultures and nations; these include burning sensation, electric shock, numbness and 
tingling sensation among others59.  Unfortunately, despite the fact that there are many poorly 
understood pathophysiological mechanisms of neuropathic pain all the types of neuropathic 
pain are lumped together and treated uniformly60.     
  In their review article Bouhassira et al (2011) described the unique characteristics of 
neuropathic pain having both positive and negative phenomena43.  The article by Hitchcock 
et al (2008) also mentioned that positive and negative phenomena have always been linked 
to neuropathic pain, but Hanpaa et al (2011) have mentioned that these phenomena also 
occur in non-neuropathic pain38,41,61.  Backonja & Krause (2003) described these phenomena 
on their work on the basis of diagnosis of neuropathic pain58.  Each type of neuropathic pain 
has a distinct, plausible anatomical explanation43.  A major problem experienced in managing 
neuropathic pain is the lack of universally accepted validated and operational diagnostic 
criteria.  However, when allodyna, hypo-algesia, hypo-aesthesia and temporal summation 
occur in a patient with pain then these features are very discriminatory for neuropathic pain38. 
Neuropathic pain has been described as part of a broader spectrum known as “pain of 
predominantly neuropathic origin” (POPNO)37,41. 
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In a multi-national, multi-centre study Crawford et al (2008) analysed the sensory descriptors 
of neuropathic pain among different nations and cultures59.  The co-authors of Crawford 
(Bouhassira, Wong and Dukes) are all well published in the field of neuropathic pain.  Their 
study confirmed the terms used by most patients with neuropathic pain:  electric shocks, 
burning sensation, tingling sensation and numbness.  The terms seemed universal across all 
the 6 countries studied.  Interestingly all the Chinese participants with extreme pain related 
their pain to the heart.  Numbness was explained as a term that may not describe pain but 
related to non-pain paraesthesia or dys-aesthesia.  The qualitative nature of their study 
allowed the subjective characteristics of pain to come out in their sensory descriptors59. 
Bennet et al (2007) and Bouhassira et al (2005) emphasized that verbal descriptors are vital 
in understanding patient’s suffering58,61.  They also highlighted that paraesthesia and dys-
aesthesia are fairly unique to neuropathic pain58. 
2.3.4 Measures of Anxiety Disorders  
The anxiety sensitivity index (ASI), as a screening tool for anxiety disorders has a good internal 
consistency with an alpha co-efficient score of 0.79-0.90 according to work done by Gonzalez 
et al (2010)5.  The Structural Clinical Interview (SCID) for Diagnostic and Statistical 4th edition 
(DSM –IV) axis I disorders (SCID-I) is the current gold standard used in the diagnosis of anxiety 
disorders (First et al)24.  The SCID clinician version (SCID-CV) was the diagnostic tool used for 
identifying anxiety disorders among PLWHIV who had neuropathic pain in this study.  The ASI 
would only pick out PLWHIV with anxiety disorders but without identifying the underlying 
type of anxiety.   SCID-CV on the other hand identifies people with anxiety disorders but also 
the type of anxiety disorder involved24.  The problem is that SCID-CV is long and tedious.   
The other clinical or research instruments used in study of anxiety disorders have only been 
discussed briefly here because they are either purely screening tools, or are tools used for 
measuring severity of each type of anxiety disorders.  With the exception of Anxiety Sensitivity 
Index (ASI) which is a useful instrument for screening for, and not for diagnosis of, anxiety 
disorders most of the other instruments are unique for evaluating each type of anxiety 
disorder5.  Most of these tools are not helpful as diagnostic tools for all the anxiety disorders 
and, hence, some of which have been briefly critiqued herein under. 
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The ASI is a tool used for measuring anxiety sensitivity in patients.  This refers to somatic 
sensations related to anxiety and fears that these sensations have harmful consequences. 
There is an accompanying fear of losing one’s mind.  This is different to trait anxiety which 
refers to fearful response to exogenous stressors, while anxiety sensitivity refers to fearful 
response to internal somatic sensations (endogenous sensations)5.  ASI is very valuable in 
identifying people at risk of panic attacks/disorder because anxiety sensitivity is important in 
maintaining panic disorder.  ASI has notably been found lacking in that sometimes it cannot 
differentiate between panic and non-panic anxiety disorder5.  Although highly elevated 
among patients with PD, ASI is also elevated among patients with PTSD.  It is slightly elevated 
among patients with SAD and those with major depressive disorder.  As a screening tool it 
tells us whether, or not a patient has an anxiety disorder or depression.  However, it is not a 
tool that we can use to diagnose a specific type of anxiety disorder5.  
The Generalized Anxiety Disorder Severity Scale (GADSS), as the name suggests is a severity 
scale with good internal consistency and reliability but unfortunately this applies only to GAD. 
It is not useful, and not applicable in the diagnosis of other anxiety disorders.  As a tool it has 
been found to be good in clinical trials involving GAD62.  It is a stronger tool for evaluating 
GAD symptoms compared to the Penn State Worry Questionnaire (PSWQ) which does not 
directly assess DSM IV symptoms62.  For assessing GAD symptoms the GADSS also compares 
favourably over the Hamilton Rating Scale for Anxiety (HAM-A) which dwells on a lot phobic 
symptoms, cardiorespiratory symptoms and gastrointestinal symptoms which are not related 
to the diagnostic symptoms of GAD62.  Again these three tools are not as useful for diagnosing 
individual anxiety disorders as the SCID-CV.   
The Spielberger State-Trait Anxiety Inventory (STAI) is an anxiety screening tool whose main 
purpose is for detecting cases.  It affords us the ability to separate patients with, and those 
without mental disorders.  It has good convergent validity and internal consistency, although 
unlike the SCID-CV it does not diagnose the different types of anxiety disorders.  It has an 
advantage though, when assessing how study participants felt at that moment of the 
interview, in the recent past and how they are likely to feel in future hypothetical situations. 
It is a tool that has been found useful in senior citizens63.     
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The Anxiety and Depression Detector (ADD) is a useful screening tool for anxiety and 
depression in primary care.  This has been bench-marked against the computerised version 
of the Composite International Diagnostic Interview (CIDI-Auto); the interviewer 
administered version of CIDI is used.  Like the SCID-CV the CIDI Auto is a structured interview 
whose responses are entered into a computer screen and automatically gives out a DSM IV 
diagnosis.  The CIDI Auto is particularly useful especially for lay interviewers in studies where 
large numbers of participants are to be interviewed.  As a screening tool ADD is good for
picking out depression, PD, PTSD, GAD and SAD at the primary care level.  Useful a tool as it 
may be, the ADD screens out the patients with the five disorders mentioned above without 
necessarily identifying each of the five diagnoses definitively.  The ADD may not be useful for 
screening for the other anxiety disorders other than the five mentioned above64. 
Another tool for evaluating anxiety disorders is Overall Anxiety Severity and Impairment Scale 
(OASIS); and is a brief 5-item tool.  It is useful in measuring severity and accompanying 
impairment across the board for all anxiety disorders, but is also not a diagnostic tool.  It may 
be used even when anxiety disorders are comorbid and in patients with sub-syndromal 
distress65.   It unfortunately lacks the diagnostic capacity of the SCID-CV.  For patients with 
panic disorder the Panic Disorder Severity Scale (PDSS) provides an easy to use tool but which 
diagnoses or assesses the severity of PD.  Although it may not diagnose the other anxiety 
disorders it can differentiate between PD and other anxiety disorders with panic attacks65. 
For the diagnosis and rating of severity of PTSD the Clinician Administered PTSD scale for DSM 
IV (CAPS) has been considered the gold standard, and is derived from the DSM IV.  CAPS has 
been found to compare well with Short PTSD Rating Interview (SPRINT) with the later taking 
less time to administer.  Unfortunately these tools are disorder specific, and not used for 
diagnosing all the other types of anxiety disorders.      
If a rating scale, or a screening tool for panic disorder were used for this study it would not be 
helpful in diagnosing PTSD or the other types of anxiety disorders among PLWHIV who had 
neuropathic pain.   The Rating Scales are useful instruments for assessing the severity of each 
anxiety disorder once a diagnosis has already been made with the help of a diagnostic tool 
such as the SCID-CV.  A case in point is the Post Traumatic Stress Diagnostic Scale (PDS) which 
is helpful within the context of patients already confirmed to have PTSD67.  When it comes to 
diagnosing anxiety disorders the SCID-CV, despite its length and some other shortcomings is 
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still considered the gold standard.  Unlike the other screening instruments mentioned above, 
the SCID-CV is not a screening tool but a diagnostic tool for anxiety disorders.  
The SCID-CV is a semi-structured instrument that permits the evaluation of most mental 
health problems of DSM-IV Axis I disorders.  Results of interview with SCID-I across countries 
and languages were similar for anxiety disorders, although our interviewers used mainly 
siSwati which is not one of the languages used for the evaluation of SCID-CV 68,69,70.  Although 
not perfect SCID-CV serves as a gold standard against which other diagnostic instruments are 
measured71-74.  Allowing for clinical judgement, for modifying and supplementing SCID-CV 
questionnaires improves reliability of interviews70,71.   
The decision tree and the skip instructions make the SCID-CV clinician friendly68,70,71.  Unlike 
other structured instruments the SCID-CV allows for the use of the patient’s vernacular to 
clarify some of the questions.  SCID-I (SCID-CV) has been used in over a thousand studies 
besides its use as a gold standard for evaluating other diagnostic instruments71,72.  
2.3.5 Measures of neuropathic pain 
Jensen’s review article (2006) on measures of neuropathic pain describes pain as an 
“experience with multiple dimensions”52.   Benson’s editorial article on neuropathic pain also 
acknowledges the “different dimensions of pain”53.  By the year 2005 Benson had noted the 
lack of expert consensus on the diagnostic criteria of neuropathic pain. There has been a 
paucity of universally accepted scales for assessing the intensity of neuropathic pain.  Despite 
its age and it being just an editorial this article still cited renowned experts in the field of pain 
management53.   
Irrespective of the multitude of diagnostic tools for neuropathic pain they all have a similar 
language; the sensory descriptors used in all of them are similar53-55.  In the editorial Benson 
(2005) critically appraises the Neuropathic Pain Scale (NPS), the Neuropathic Pain Symptom 
Inventory (NPSI), the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), 
Neuropathic Pain Questionnaire (NPQ), the NPQ-short form (NPQ-SF) and the Douleur 
Neuropathique 4 (French) or the Neuropathic Pain 4 questions (DN4) by looking at the pros 
and cons of each tool53.  Each of these tools has unique immense values in some specific area 
of clinical practice or research43,53.   
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The basis of most of the diagnostic tools that are used for measuring neuropathic pain is 
subjective verbal descriptors with, or without bed side examination.  As recent as the year 
2012 there was still no gold standard instrument for the diagnosis of neuropathic pain despite 
this being a very old problem (Chetty et al, 2012)42.  There is still a status quo as compared to 
a similar older report by Bennet et al (2007).  The Leeds Assessment of Neuropathic Signs and 
Symptoms (LANSS) was the first instrument developed for the measurement of neuropathic 
pain with a sensitivity of 85% and specificity of 80%54,56.  LANSS includes both an interview 
and bed side examination. Bennet co-authored many articles on pain, especially neuropathic 
pain56.  The NPS stood out as a tool useful for evaluating therapeutic outcome measures and 
the advantage of the NPQ-SF is its brevity53.  The NPS assesses pain qualities such as intensity, 
unpleasantness and unique time characteristics53.       
 The DN4 questionnaire stood out for its ease of administration with its YES/NO answer 
format.  The DN4 scored highly on predictive value (85%) and sensitivity (82.9%) and 
specificity (89.9%).  The characteristic sensory descriptors in the DN4 are:  Burning sensation, 
cold sensation, electric shocks, tingling, pins & needles, numbness, itchiness, hypo-aesthesia 
to pin-prick, increased pain with brushing and hypo-aesthesia to touch53,54. 
Even without the examination component the 7 sensory descriptors have a high accuracy 
according to Bennet et al; and this is then called the DN4 interview54.  The DN4 was the 
screening tool used for diagnosing neuropathic among the PLWHA who took part in this study 
in Nkomazi district health clinics in South Africa.  Other diagnostic instruments for 
neuropathic pain are the self-report version of LANSS (s-LANSS), Pain Quality Assessment 
Scale (PQAS) and Pain DETECT and ID-Pain52-61.  This is an internationally validated tool 
although not validated in RSA, and more specifically not validated in Nkomazi sub-district.  
The sensory descriptors of the DN4 Interview make a good tool for accurately diagnosing 
neuropathic pain54.    
 Previous studies on anxiety disorders and/or pain in Nkomazi sub-district 
It was not possible to identify any publications in respect of the above in the sites searched. 
However, in an unpublished study (Ochan, 2010) among unselected private patients in 6 
Nkomazi rural medical practices in 2010 the rate of anxiety disorders was as high as 74.67%, 
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with PTSD being the most prevalent (29.33%), followed by PD (24%), adjustment disorder 
(14.67%) and other anxiety disorders (13.3%)75.  This study has the weakness of having been 
conducted in the private medical setting only (and not among public sector patients), being a 
prevalence study and it had not stood the test of a published article.    
Considering the work that has been reviewed above, there is a lot that has been done on the 
relationship between anxiety and pain in the general population and PLWHIV.  However, 
there is a gap on the prevalence of anxiety disorders among PLWHIV who also experience 
neuropathic pain in Nkomazi sub district in Mpumalanga Province of South Africa.  
The Problem Statement 
The motivation to investigate the prevalence of anxiety disorders among PLWHIV with 
neuropathic pain in Nkomazi public health clinics in South Africa was that: 
Anxiety disorders do make people prone to HIV infection and PLWHIV are also prone to 
developing anxiety disorders9,22,27,28,51.  Likewise screening for anxiety disorders in all PLWHIV 
reduces symptom burden in this subpopulation; and the anxiety disorders affect adherence 
to HIV/AIDS treatment19,20,25,28,30,31.  Nkomazi sub-district is in Mpumalanga province which 
has one of the highest rates of HIV infection in South Africa1; and it is likely that pain and 
anxiety disorders among PLWHIV are under-diagnosed and under-treated.   
Immense suffering accompanies neuropathic pain27,36,44-46 and central sensitization modifies 
pain modulation in the same neural pathways involved in processing anxiety47,48.  Anxiety 
disorders are more prevalent in people at risk of HIV infection even when uninfected43,50,51. 
The intricate interplay between pain and anxiety disorders in PLWHIV was the basis for doing 
this study2,9-12,21; and more so what the prevalence of anxiety disorders would be if the pain 
experienced by PLWHIV was neuropathic in nature.   
3. AIM OF THE STUDY
To determine the prevalence of anxiety disorders among PLWHIV neuropathic pain who
attended HAART clinics in Nkomazi sub-district. 
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Objectives of the study: 
1 To determine the prevalence of Neuropathic Pain among patients attending HIV clinics in 
Nkomazi Health District. 
2 To determine the prevalence of all Anxiety disorders among PLWHIV with neuropathic pain 
3 To determine the types of anxiety disorders among Nkomazi PLWHIV who have NeuP.  
4. METHODOLOGY
4.1 Study Design 
To achieve the objectives an observational, cross-sectional study design with descriptive and 
analytical components was used. This study design was chosen because it is cheap and easy to 
conduct; and allowed for a snapshot view of the predictors of neuropathic pain and anxiety 
disorders amongst PLWHIV. This design also allowed for the determination of prevalence of 
both neuropathic pain and anxiety disorders in the study population.  
4.2 Study Setting 
The Study was conducted in Nkomazi Sub-district, which serves as one of five Sub-districts in 
the Ehlanzeni District in South Africa’s Mpumalanga Province. This Sub-district has the 3rd 
largest population in the District having at least 23% of the District residents76. This Sub-
district was conveniently chosen because of its size and the fact that it shares borders with both 
Swaziland and Mozambique. Furthermore, this is one of the most deprived Sub-districts in the 
country76. The Sub-district has 34 fixed Primary Care facilities, three of them were sampled 
for this study.  
4.3 Study Population 
This included all patients on HAART that attended nurse-run HAART clinics in Nkomazi sub-
District between the 2nd of April 2013 and the 2nd of May 2013.  
4.3.1 Patient Selection Criteria 
Inclusion Criteria 
-Adult Patients living with HIV
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-Anxiety disorders were only diagnosed in those participants who had neuropathic pain, and
all the other participants without neuropathic pain were then excluded from this component of 
the study. 
-All those adult patients had to be on HAART.
- Patients who were fit to consent.
- Participants issued a voluntary consent before participating in the study.
Exclusion Criteria 
-Patients younger than 18 years of age.
-Patients who were too weak or unwell to manage interview,
-Those with mental retardation and/or those with neurological or cognitive impairment.
-Patients waiting for initiation of HAART, or those who have stopped taking HAART, were
not included in the study. 
4.3.2 Sampling 
4.3.2.1 Sample Size Calculation 





n = minimum sample size; p = estimated prevalence of neuropathic pain or anxiety disorders; 
d = precision; Z= 1.96 (at the 5% significance level). Because there are two outcomes (anxiety 
disorders and neuropathic pain, two sample sizes were calculated).  
1) With an estimated prevalence of neuropathic pain among PLWHA in RSA of 20.9%41, the
expected sample size (n) is 254 with a precision of 5% around the 95% confidence interval 
(CI).   
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2) Globally the prevalence of Anxiety disorders among PLWHIV is 4-40%78 and the sample size
may be calculated using the following anticipated prevalence: (a) expected prevalence of 
anxiety disorders of 10.0%, n=384 with a precision of 3% around the 95% CI, (b) expected 
prevalence of anxiety disorders of 30.0%%, n=322 with a precision around 5% the 95% CI.   
The sample size (n=384) with the smallest prevalence of 10% would give a reasonable 
estimate for both outcome measures.   The sample size used in this study was 508, much 
higher than the calculated minimum of 384 participants. 
4.3.2.2 Sampling Method 
A convenient cluster sampling method was used to identify facilities. Participants were 
identified using a systematic random sampling method. The processes are described below:   
Stage 1 was a convenience sampling of the 3 of the 34 nurse-run HIV treatment clinics.  This 
was determined by looking at the monthly and annual figures of PLWHA that used all the 34 
clinics of Nkomazi district.  The reasons for using only 3 clinics were figures, costs and 
proximity of these centers to the medical practice of the researcher.   
Stage 2 involved a systematic sampling of every 3rd patient attending each of the selected 
clinics until 508 participants had been interviewed.  This resulted from an error that is 
explained later. 
4.4 Instruments and Data Collection 
Participant interviews were conducted in a private space which ensured confidentiality of 
respondents. 
4.4.1 The variables measured were: 
-The clinical features of neuropathic pain.
-The clinical features of the different anxiety disorders.
4.4.2 The data collection tools that were used in the study were: 
29 | P a g e
i. Socio-demographic data were collected from all participants. These included:  Gender, Age,
Language, Educational status, Employment status and level of income. Race was not collected 
as the population is homogenous. The level of education does not necessarily mean attainment 
but rather means some contact with that level, e.g. someone who is listed as having a primary 
school level of education could for instance have only attended only 1-year or 7-years. 
ii. The Structured Clinical Interview DSM IV Axis I Disorders (Clinicians’ Version), SCID-
CV,  is a validated instrument although validation was not done in the sub-population studied 
in Nkomazi sub-district. We excluded the over-view part of the SCID-CV which would cover 
the socio-demographic data and past psychiatric/medical history of the patient65; instead a 
shorter more concise socio-demographic questionnaire was used. The adopted questionnaire 
was translated to siSwati (the local language).  
Module F of the SCID-I (clinician version, CV) of the DSM-IV was chosen for the diagnosis 
of anxiety disorders among PLWHA in Nkomazi.  Our research assistants interviewed the 
majority of the participants in siSwati language with a few opting for xiTsonga, another 
language spoken in Nkomazi sub-district.  The design of SCID-CV allowed us to extract all 
necessary information to help arrive at diagnostic decisions and also gave our interviewers 
room for flexibility to help clarify equivocal responses.  Interviewers received satisfactory, 
however very brief training on the use of the SCID-CV.  
iii. The DN4 interview.
The DN4 interview is a shorter version of the DN4 tool for identifying neuropathic pain in 
patients. Sensitivity is about 83% (82.9%) and specificity is about 90% (89.9%).   
4.4.3 Data collection methods 
The research assistants were nurses who were recruited, trained and tested on research ethics 
and the use of the DN4 Interview and SCID-CV questionnaires. Training of the research 
assistants involved going through the theories behind each of the tools. The assistants were 
then taught to administer the tools to the researcher in simulated interviews, and were observed 
while interviewing randomly picked patients from each of the 3 participating clinics.     
Obtaining of the informed consent: 
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Trained research assistants explained the study to potential participants. There was detailed 
and complete disclosure of information regarding the study.  To most of the patients this was 
explained in si-Swati, the language spoken by the majority in Nkomazi. A private space at each 
clinic was used for this purpose.  Understanding of “whether the participants knew what they 
were getting themselves into’’ was assessed by requesting them to briefly repeat what the 
study entailed. The participants were advised that they could withdraw at any stage of the 
study and that they would continue to receive usual care. The patients agreed to take part in 
the study then signed the consent form.  
 The foundation of informed consent was the competence of the participant to understand 
and decide.  All participants had to be mentally competent and not too sickly or weak. The 
participants were not coerced, voluntariness was respected as was explained to research 
assistants during their training.  Whether, or not, patients participated in the study did not 
affect the way they were treated by each clinic.  The only difference was a can of cold 
beverage and a pack of snacks was offered to each study participant after the interview; and 
the participants did not know about this prior to the interview.  Refreshment was only offered 
after the interview. 
Recruitment of participants: 
Participants were recruited on clinic days dedicated for follow-up of patients on HAART. The 
4 Research Assistants (RAs) did the recruitment of participants. A simple random sampling 
was used to select the first participant; thereafter systematic random sampling was used.  
Diagnosis of Neuropathic Pain and Anxiety 
Participants were asked if they had any nagging (significant) pain over the past month. The 
DN4-Interview was then administered to all patients who had pain for a month, or longer. All 
patients who scored at least 4 out of 7 on the DN4-Interview were diagnosed as having 
neuropathic pain.  The SCID-CV was then administered to all the patients who were diagnosed 
with neuropathic pain. The SCID-CV was administered as a diagnostic tool for anxiety 
disorders amongst PLWHIV who had neuropathic pain. The SCID-CV, was preferred over an 
anxiety screening tool because the aim of the study was to identify any of the anxiety disorders 
in patients who had neuropathic pain.     
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The RAs kept all the questionnaires securely and handed them over to the principal investigator 
(PI) at the end of each clinic day. 
4.4.4 Ethical considerations 
The Research Proposal was approved by the University of Cape Town (UCT), Faculty of 
Health Sciences Human Ethics Research Committee (Ref 587/2012).  The proposal was then 
submitted to the Mpumalanga Department of Health Provincial Human Research Ethics 
Committee which gave access approval. Ethical standards in keeping with the four principles 
of Autonomy, Beneficence, Non-maleficence and Justice were upheld. For instance; patient 
confidentiality was maintained and patients had the right to consent and withdraw at any stage 
of the study regardless of the reason. If a participant needed health care they were channeled 
to the sister-in-charge to manage further. The two heads of government clinics in the Nkomazi 
East and West gave written permission for the study to be conducted at the clinics in Nkomazi 
Sub-district.  
4.4.5 Data Storage 
A lockable case was provided for safe-keeping of the completed questionnaires. At the end of 
each clinic day the research assistants delivered the locked case with all the consent forms and 
completed questionnaires to the PI. The consent forms and questionnaires shall be kept locked 
and safe for not less than 5 years before they shall be safely disposed of.  
This was the phase during which a tally of all incoming questionnaires should have been kept 
from day one; unfortunately this was not done.  The calculated number of study participants 
(384) would not have been exceeded had a tally been initiated at the very beginning, instead
of just eyeballing the incoming completed forms and relying on estimation.  The PI 
underestimated the rate at which the interviews were conducted. 
4.4.6 Data Analysis 
All data collected were coded and entered in Microsoft excel 2010 (Microsoft corporation, 
Seattle, USA, USA) and exported into Stata 14.1 (STATA Corp LP, College station, Texas, 
USA) for analysis. The analyses report on three outcomes; that being general pain, neuropathic 
pain and anxiety disorders. Numerical variables were explored for normality using histogram, 
box-and-whisker plot and the Shapiro Wilk test. Age is reported on both as a numerical variable 
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and as an ordinal categorical variable. Age was not normally distributed, as a result it is 
summarized using the Interquartile Range (IQR) and median (non-parametric statistics). The 
Wilcoxon sum rank test is used to test the differences between two medians e.g. age differences 
in those with pain and those without pain, etc. 
Univariate analysis of Categorical variables is summarized using proportions/percentages and 
a bar graph. The two sample test of proportions is used to compare the differences between two 
proportions. In a case where there are more than two categories, one of the categories is used 
as a reference category to allow for this binary comparison. Testing for an association between 
two categorical variables was conducted using the Chi-squared test or the Fisher’s Exact test 
depending on the value of the expected frequencies. If <5 the Fisher’s exact test was used. 
However, if the expected frequencies were <5 then the Fisher’s exact test is used. Since this is 
a Cross-sectional study, the Prevalence Ratio (PR) is the relative measure of association used 
for reporting. The 95% Confidence Interval (95% CI) is used to show the precision of estimates. 
The level of significance was set at 5% (p-value <=0.05).    
5. RESULTS
A total number of 508 patients were included in the study. Participants were more likely to be 
interviewed at kaMhlushwa clinic (n = 203 or 39.96%; 95% CI: 35.67 – 44.37) than being 
interviewed at Naas clinic (n = 126 or 24.80%; 95% CI: 21.11 – 28.80). Similarly the 
proportion of participants interviewed at Mangweni clinic (n = 179 or 35.24%; 95% CI: 31.08 
– 39.57) were more than those interviewed at Naas clinic (Table1).
Patient Demographics 
Table 1 further shows the demographic characteristics of participants. There were more females 
(77.56%; 95% CI: 73.68 – 81.12; n = 394) than males (22.44%; 95% CI: 18.88 – 26.32; n = 
114) in the sample. Furthermore, females were significantly more likely to be younger (median
age = 36) than their male counterparts (median age = 39.50; p-value = 0.0001). Whilst 25% of 
all females were below the age of 30, only 25% of females were older than 43 years of age. In 
contrast to males where 25% of them were older than 48 years of age. 
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SiSwati was considered to be the home language for 77.56%; 95% CI: 73.68 – 81.12 (n = 394) 
of participants followed by xiTsonga (19.09%; 95% CI: 15.77 – 22.79; n = 97). Even though 
over half of the participants (51.97%; 95% CI: 47.52 – 56.39; n = 264) had some secondary 
education, 45.47%; 95% CI: 41.08 – 49.92 (n = 231) of the participants either had no education 
at all or had some primary education. Only 505 (99.41%; 95% CI: 98.28 – 99.88) participants 
responded on questions about employment status and their monthly income.  
Most respondents (73.27%; 95% CI: 69.18 – 77.08; n = 370) were unemployed and most had 
no income at all (57.43%; 95% CI: 52.98 – 61.78; n = 290). Even though females comprised 
68.89% (n =93; 95% CI: 60.36 – 76.57) of the employed respondents (n = 135), a significantly 
higher proportion of males was employed (n = 42 or 36.84%; 95% CI: 27.99 – 45.70) as 
opposed to females (n = 93 or 23.79%; 95% CI: 19.65 – 28.32). 
Table 1: Patient Characteristics and Demographics (508 participants) 
CLINIC n (%;  95% Confidence interval) p-value
Naas 126 (24.80; 21.05 – 28.56) 1 
Mangweni 179 (35.24; 31.08 – 39.39) 0.0003 
KaMhlushwa 203 (39.96; 35.70 – 44.22) < 0.0001 
Total 508 (100) 
SEX n (%;  95% Confidence interval) p-value
Female 394 (77.56; 73.93 – 81.19) 
<0.0001 Male 114 (22.44; 18.81 – 26.07) 
Total 508 (100) 
AGE (Years) n (%;  95% Confidence interval) p-value
18 – 30 132 (25.98; 22.17 – 29.80) 1 
31 – 40 194 (38.19; 33.96 – 42.41) <0.0001 
41 – 50 122 (24.02) 0.469 
>50 60 (11.81) <0.0001 
Total 508 (100) 
AGE (Years) by SEX Interquartile Range Median p-value
Female 30 – 43 36 
0.0001 Male 33 – 48 39.50 
LANGUAGE n (%;  95% Confidence interval) p-value
siSwati 394 (77.56; 73.93 – 81.19) 1 
xiTsonga 97 (19.09; 15.68 – 22.51) <0.0001 
Other 17 (3.35; 1.78 – 4.91) <0.0001 
Total 508 (100) 
RELIGION n (%; 95% Confidence interval) p-value
Christian 471 (92.72; 90.46  -94.98) 1 
Muslim 1 (0.20; -0.19 – 0.58) <0.0001 
African 16 (3.15; 1.63 – 4.67) <0.0001 
Other 20 (3.94; 2.25 – 5.63) <0.0001 
Total 508 (100) 
EDUCATION n (%; 95% Confidence interval) p-value
None 96 (18.90; 15.49 – 22.30) 1 
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Primary School 135 (26.57; 22.73 – 30.42) 0.004 
Secondary 264 (51.97; 47.62 – 56.31) <0.0001 
Tertiary 13 (2.56; 1.19 – 3.93) <0.0001 
Total 508 (100) 
EMPLOYMENT n (%; 95% Confidence interval) p-value
Yes 135 (26.73; 22.87 – 30.59) 
< 0.0001 No 370 (73.27; 6.94 – 77.13) 
Total 505 (100) 
Monthly Income (Rand) n (%; 95% Confidence interval) p-value
None 290 (57.43; 53.11 – 61.74) 1 
< 1000 99 (19.60; 16.14 – 23.07) <0.0001 
1000 – 4 999 105 (20.79; 17.25 – 24.33) <0.0001 
≥5000 11 (2.18; 0.91 – 3.45) <0.0001 
Total 505 (100) 
When age and gender are used as a measure of demographic characteristics, Table 2 shows 
that participants had similar characteristics between the 3 facilities.  
Table 2: Comparison of basic demographics by Facility 
Gender Naas: n (%) Mangweni: n (%) KaMhlushwa: n (%) p-value
Female 96 (76.19) 145 (81.01) 153 (75.37) 0.384 
Male 30 (23.81) 34 (18.99) 50 (24.63) 
Age Group 
(Years) 
Naas: n (%) Mangweni: n (%) KaMhlushwa: n (%) p-value
18 – 30 36 (28.57) 44 (24.58) 52 (25.62) 
0.913 31 – 40 50 (39.68) 71 (39.66) 73 (35.96) 
41-50 27 (21.43) 44 (24.58) 51 (25.12) 
>50 13 (10.32) 20 (11.17) 27 (13.30) 
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Univariate Analysis of Outcome variables 
Table 3 is the most vital of all the tables in the results chapter, the corner stone of this study 
and is the answer to the aim of the study.  Of all the participants, 46.06%; 95% CI: 41.66 – 
50.51 (n = 234) described having at least some pain when screened. Similarly, there were 
individuals with neuropathic pain (17.72%; 95% CI: 14.49 – 21.32; n = 90) and the majority 
of those with pain had no neuropathic pain (82.28%; 95% CI: 78.68 – 85.51; n = 418). Table 
3, also shows that 80%; 95% CI: 70.25 – 87.69 (n = 72) of respondents who had neuropathic 
pain (n = 90) had anxiety disorders. It has to however, be noted that anxiety disorders were 
only assessed in those patients with Neuropathic pain (n = 90).  
A detailed analysis (Figure 1) showed that the majority of participants (n = 40; 55.56%; 95% 
CI: 43.36 – 67.28) who had an anxiety disorder had a panic disorder. Just over a quarter of 
anxiety disorders (26.39%; 95% CI: 16.70 – 38.10; n = 19) were due to Post-Traumatic Stress 
disorders (PTSD) followed by Other Anxiety disorders (n = 7) and Obsessive Compulsive 
Disorders (n = 2). Somatoform disorders, eating disorders, adjustment disorders and anxiety 
disorders due to general medical conditions each accounted for a single case of an anxiety 
disorder (n = 1). 
Table 3: Univariate Analysis of Outcome Variables 
PAIN n (%;  95% Confidence 
interval) 
p-value
Yes 234 (46.06; 41.73 – 50.40) 0.012 
No 274 (53.94; 49.60 – 58.27) 
NEUROPATHIC PAIN n (%;  95% Confidence 
interval) 
p-value
Yes 90 (17.72; 14.40 – 21.04) <0.0001 
No 418 ( 82.28; 78.96 – 85.60) 
ANXIETY DISORDER n (%;  95% Confidence 
interval) 
p-value
Yes 72 (80; 71.74 – 88.26) <0.0001 
No 18 (20; 11.74 – 28.26) 
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Association of pain with demographic characteristics 
Table 4: Association of Pain with Demographic Characteristics 
Variable Category n (%) PR (95% CI) p-value
Yes No 
CLINIC Naas 26(20.63) 100 (79.37) 1 1 
Mangweni 19 (10.61) 160 (89.39) 1.94 (1.13 – 3.36) 0.015 
KaMhlushwa 189 (80.77) 14 (6.90) 0.22 (0.16 – 0.31) <0.0001 
Total 234 (46.06) 274 (53.94) 
SEX Female 178 (45.18) 216 (54.82) 1 1 
Male 56 (49.12) 58 (50.88) 0.92 (0.74 – 1.14) 0.457 
AGE (Years) 18 – 30 57 (43.18) 75 (56.82) 1 1 
31 – 40 77 (39.69) 117 (60.31) 1.09 (0.84 – 1.41) 0.529 
41 – 50 64 (52.46) 58 (47.54) 0.82 (0.64 – 1.07) 0.139 
>50 36 (60) 24 (40) 0.72 (0.54 – 0.96) 0.031 
LANGUAGE Siswati 172 (43.65) 222 (56.35) 1 1 
xiTsonga 51 (52.58) 46 (47.42) 0.83 (0.67 – 1.03) 0.114 
Other 11 (64.71) 6 (35.29) 0.67 (0.47 – 0.98) 0.087 
RELIGION Christian 213 (45.22) 258 (54.78) 1 1 
Muslim 0 1 (100) N/A 0.549 
African 6 (37.50) 10 (62.50) 1.21 (0.64 – 2.29) 0.541 
Other 15 (75.00) 5 (25.00) 0.60 (0.46 – 0.79) 0.009 
EDUCATION None 56 (58.33) 40 (41.67) 1 1 
Primary 
School 
54 (40) 81 (60) 1.46 (1.12 – 1.90) 0.006 
Secondary 117 (44.32) 147 (55.68) 1.32 (1.06 – 1.63) 0.019 
Tertiary 7 (53.85) 6 (46.15) 1.08 (0.64 – 1.84) 0.759 
EMPLOYMENT Yes 63 (46.67) 72 (53.33) 1 1 




None 94 (32.41) 196 (67.59) 1 1 
< 1000 80 (80.81) 19 (19.19) 0.40 (0.33 – 0.49) <0.0001 
1000 – 4 999 55 (52.38) 50 (47.62) 0.62 (0.48 – 0.79) 0.0003 
≥5000 5 (45.45) 6 (54.55) 0.71 (0.37 – 1.39) 0.366 
Age (Years) Category n (%) IQR (Years) Median (Years) p-value
Pain 234 (46.06) 31 – 48 38 
0.005 No pain 274 (53.94 30 – 42 35.5 
Total 508 (100) 30 – 45 37 
When clinics were compared, kaMhlushwa had the majority of patients with pain (Table 4). In 
fact, pain was prevalent in 80.77%; 95% CI: 75.13 – 85.61 (n = 189) of the participants from 
kaMhlushwa clinic. It was further found that patients from Naas clinic were 22% less likely to 
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report pain than patients from kaMhlushwa clinic and this was statistically significant (PR = 
0.22; p-value <0.0001). When compared to participants from Mangweni clinic, those from 
Naas were 94% more likely to experience pain than those from Mangweni clinic, this 
association was also statistically significant (PR = 1.94; p-value = 0.015).  
There was no statistical difference in the gender characteristics of patients who reported pain 
and those who did not (PR = 0.92; p-value = 0.457).  Patients with pain were more likely to be 
older (median age of 38) compared to those without pain (median = 35.5) and this was 
statistically significant (p-value = 0.005).  Furthermore, participants younger than 31 years of 
age were found to be 28% less likely to report pain than those older than 50, this was also 
statistically significant (PR = 0.72; p-value = 0.031).  
Even though there was no statistical difference in pain experiences of those with tertiary 
education and those with no education at all (PR = 1.08; p-value = 0.759); those without 
education were 46% more likely to report pain that those with primary school education, this 
was statistically significant (PR = 1.46; p-value = 0.006). Similarly, having no education at all 
increased the likelihood of reporting pain by 32% (PR = 1.32; p-value = 0.019).    
Neuropathic Pain 
As mentioned under Univariate analysis of outcome variables and indicated in Table 5, 
neuropathic pain among all the study participants was prevalent in 17.72% (n =90; 95% CI: 
14.49 – 21.32) of the participants. However, if only those with pain are considered (n = 234), 
the prevalence of neuropathic pain in this subgroup was 38.46% (95% CI = 32.20 – 45.02).  Of 
all the clinics, neuropathic pain prevalence was highest in KaMhlushwa clinic (28.57%; 95% 
CI: 22.47 – 35.32; n = 58) this is 64.44% (95% CI: 53.65 – 74.26) of all the neuropathic pain 
cases (n = 90).  Shown in Table 4 is that patients from Naas clinic were 53% less likely to have 
neuropathic pain compared to patients from KaMhlushwa clinic (PR = 0.47; p-value = 0.0002).  
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Table 5: Bivariate Analysis of Demographic Characteristics and Neuropathic pain 
Variable Category n (%) PR (95% CI) p-value
Yes No 
CLINIC Naas 17 (13.49) 109 (86.51) 1 1 
Mangweni 15 (8.38) 164 (91.62) 1.61 (0.84 – 3.10) 0.151 
KaMhlushwa 58 (28.57) 145 (71.43) 0.47 (0.29 – 0.77) 0.002 
Total 90 (17.72) 418 (82.28) 
SEX Female 71 (18.02) 323 (81.98) 1 1 
Male 19 (16.67) 95 (83.33) 1.08 (0.68 – 1.72) 0.739 
AGE (Years) 18 – 30 20 (15.15) 112 (84.85) 1 1 
31 – 40 26 (13.40) 168 (86.60) 1.13 (0.66 – 1.94) 0.656 
41 – 50 26 (21.31) 96 (78.69) 0.71 (0.42 – 1.21) 0.203 
>50 18 (30) 42 (70) 0.51 (0.29 – 0.88) 0.017 
LANGUAGE Siswati 70 (17.77) 324 (82.23) 1 1 
xiTsonga 17 (17.53) 80 (82.47) 1.01 (0.63 – 1.64) 0.956 
Other 3 (17.65) 14 (82.35) 1.01 (0.35 – 2.87) 0.644 
RELIGION Christian 85 (18.05%) 386 (81.95) 1 1 
Muslim 0 1 (100) N/A 0.820 
African 2 (12.50) 14 (87.50) 1.44 (0.39 – 5.35) 0.433 
Other 3 (15) 18 (85) 1.20 (0.42 – 3.48) 0.504 
EDUCATION None 23 (23.96) 73 (76.04) 1 1 
Primary 
School 
15 (11.11) 120 (88.89) 2.16 (1.19 – 3.91) 0.009 
Secondary 48 (18.18) 216 (81.82) 1.32 (0.85 – 2.04) 0.223 
Tertiary 4 (30.77) 9 (69.23) 0.78 (0.32 – 1.90) 0.593 
EMPLOYMENT Yes 27 (30) 63 (70) 1 1 




None 42 (14.48) 248 (85.52) 1 1 
< 1000 24 (24.24) 75 (75.76) 0.60 (0.38 – 0.93) 0.026 
1000 – 4 999 22 (20.95) 83 (79.05) 0.69 (0.43 – 1.10) 0.123 
≥5000 2 (18.18) 9 (81.82) 0.80 (0.22 – 2.88) 0.496 
Age (Years) Category n (%) IQR (Years) Median (Years) p-value
Neuropathic 
Pain 




418 (82.28) 30 – 44 37 
Total 508 (100) 30 – 45 37 
Once more there was no statistical difference in the prevalence of neuropathic pain in males 
and females (PR = 1.08; p-value = 0.739). However, the age pattern was similar to that of 
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general pain in that those with neuropathic pain were significantly older than those without 
neuropathic pain (p-value = 0.017). Further found was that those younger than 31 years of age 
were 49% less likely to have neuropathic pain than those older than 50 years of age (PR = 0.51; 
p-value = 0.017).
There was no statistically significant association between religion, language, or employment 
status with neuropathic pain (Table 5). Having no income at all, however, made it 40% less 
likely for participants to be diagnosed with neuropathic pain compared to those who had an 
income of < R1000 and this was statistically significant (PR =60; p-value = 0.026). In addition, 
those without education were at least 2 times more likely to have neuropathic pain than those 
with some primary school education (PR= 2.16; p-value = 0.009). All the other level of 
education categories were not statistically significant.   
Bivariate Analysis of Demographic characteristics and Anxiety Disorders 
As previously highlighted, the prevalence of anxiety disorders was 80% (n = 72; 95% CI: 71.74 
– 88.26) in the study sample who were diagnosed with neuropathic pain. Participants who were
interviewed from kaMhlushwa clinic were ±17% more likely to be diagnosed with an anxiety 
disorder when compared to participants who were seen at Naas clinic (PR = 1.17; 95% CI: 0.84 
– 1.63; p-value = 0.308). Even though a comparison of participants between the age of 18 to
31 and other age categories did not yield a statistically significant difference in their diagnoses 
of an anxiety disorder; participants with an anxiety disorder were slightly older but this was 
not statistically significant (median age of 41.5 years compared to 38) with a p-value of 
0.984.Neither gender, language, education, religion, employment nor income were statistically 
associated with anxiety disorders. Table 6 shows a summary of the bivariate association of 
anxiety disorders and demographic characteristics. 
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Table 6: Bivariate Analysis of Demographic Characteristics and Anxiety Disorders 
Variable Category n (%) PR (95% CI) p-value
Yes No 
CLINIC Naas 12 (70.59) 5 (29.41) 1 1 
Mangweni 12 (80) 3 (20) 0.88 (0.59 – 1.31) 0.691 
KaMhlushwa 48 (82.76) 10 (17.24) 0.85 (0.61 – 1.18) 0.308 
Total 72 (80) 18 (20) 
SEX Female 57 (80.28) 14 (19.72) 1 1 
Male 15 (78.95) 4 (21.05) 1.02 (0.78 – 1.32) 1.00 
AGE (Years) 18 – 30 15 (75) 5 (25) 1 1 
31 – 40 20 (76.92) 6 (23.08) 0.98 (0.70 – 1.36) 1.00 
41 – 50 24 (92.31) 2 (7.69) 0.81 (0.62 – 1.07) 0.213 
>50 13 (72.22) 5 (27.78) 1.04 (0.71 – 1.52) 1.00 
LANGUAGE Siswati 53 (75.71) 17 (24.29) 1 1 
xiTsonga 16 (94.12) 1 (5.88) 0.80 (0.67 – 0.96) 0.178 
Other 3 (100) 0 N/A N/A 
RELIGION Christian 68 (80) 17 (20) 1 1 
Muslim 0 0 N/A N/A 
African 2 (100) 0 N/A N/A 
Other 2 (66.67) 1 (33.33) 1.2 (0.54 – 2.69) 0.501 
EDUCATION None 18 (78.26) 5 (21.74) 1 1 
Primary 
School 
11 (73.33) 4 (26.67) 1.07 (0.73 – 1.55) 1.00 
Secondary 39 (14.77) 9 (18.75) 0.96 (0.75 – 1.24) 0.759 
Tertiary 4 (100) 0 N/A N/A 
EMPLOYMENT Yes 22 (81.48) 5 (18.52) 1 1 




None 35 (83.33) 7 (16.67) 1 1 
< 1000 18 (75) 6 (25) 1.11 (0.85 – 1.45) 0.523 
1000 – 4 999 18 (81.82) 4 (18.18) 1.02 (0.80 – 1.29) 1.00 
≥5000 1 (50) 1 (50) 1.67 (0.41 – 6.71) 0.334 
Age (Years) 
Category n (%) IQR (Years) Median (Years) p-value
Anxiety 
Disorders 
72 (80) 32 – 50 41.5 0.984 
No Anxiety 
Disorder 
18 (20) 30 – 51 38 
Total 90 30 – 50 39.5 
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6. DISCUSSION
6.1 Introduction 
There appears to be a gap in the literature with regards to studies that specifically research the 
prevalence of comorbid neuropathic pain and anxiety disorders among PLWHIV. This study 
was conducted in a high HIV prevalence setting in the Mpumalanga Province of South Africa, 
as the two conditions appeared to be highly prevalent in clinical practice and additional 
knowledge may be able to contribute to the literature and influence practice for better patient 
outcomes.  
6.2 Pain Prevalence 
Of note is the fact that patients at KaMhlushwa reported a high prevalence of pain whereas 
patients at the other two clinics reported a much lower prevalence of pain.  The high prevalence 
of pain in kaMhlushwa clinic is consistent with literature that reported a pain prevalence of 
84%32,39,40. It is important to consider the possible reasons behind the difference in pain 
prevalence between the three clinics:  
-It may be that pain was better assessed and managed at the Mangweni and Naas clinics than
at kaMhlushwa clinic.  There has recently been an increase in effort by national department of 
health to improve pain control primary health care facilities (anecdote).  
-The other possible explanation is that of reporting bias in that pain was underreported at
Mangweni and Naas clinics. 
The KaMhlushwa figures are in keeping with the fact that several factors threaten emotional 
health in those diagnosed with HIV, including coping with physical pain, worry about health, 
disrupting social life, isolation, fear of disclosure, anger and worry about self-image25 and this 
impacts on a patient’s pain experience.  A previous South African Primary Care morbidity 
profile that sampled facilities from 4 of the countries Provinces (Limpopo, North West and 
Mpumalanga) found pain to be the primary presenting complaint in ±23.9% of Primary Care 
presentations 79.  Although that primary care study did not look only at PLWHIV but all patients 
irrespective of their HIV serological status.  
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6.3 Bio-Medical data from the Study 
This study in Nkomazi sub-district found that the pain experience was not discriminatory by 
gender, employment status, language and/or religion of PLWHIV from Nkomazi. In the 
literature lack of employment and the subsequent low socio-economic status intensifies pain 
experience and increases the prevalence of pain5.  However, patients with pain were more likely 
to be older compared to those without pain (p-value = 0.005). Clinical research indicates that 
pain is perceived, assessed, experienced and even treated differently depending on a person’s 
gender, race or ethnicity and age80.   Age differences in pain experience are less consistent81,82.  
Some studies indicate older adults to be more sensitive to experimental pain than young adults, 
whereas others suggest a decrease in sensitivity with age81,82.  Although the  literature describes 
that 32,35,42 women have been found to be more susceptible to neuropathic pain than males32,35,42, 
there was no statistically significant difference in the prevalence of neuropathic pain by gender 
in this study.   
6.4 Neuropathic Pain 
Neuropathic pain among this Nkomazi cohort was 17.72% which is comparable to 20.9% in 
an earlier South African study in an academic setting which looked at the prevalence of 
PLWHIH but who had not yet initiated HAART unlike the patients in this study41; and it is 
recognised as being difficult to treat and needs focused attention.  The Nkomazi study might 
have therefore given patients an opportunity to report their pain as questions pertaining to pain 
were directly asked to patients who would, ordinarily have only come to collect medications 
and perform routine investigations.   
A previous study in an urban academic setting in South Africa estimated the prevalence pain 
of predominantly neuropathic origin (POPNO) in pre-HAART patients to be at ±20.9%41. 
Even though the populations can be said to be different in terms of their geography and their 
HAART status, the neuropathic pain prevalence of 17.72% among the Nkomazi cohort of 
patients in this study is comparable.  The fact that neuropathic pain was prevalent among 
38.46% of the Nkomazi PLWHIV who reported pain of all types from this study demonstrates 
the seriousness of this problem in rural Nkomazi.      
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The high prevalence of neuropathic pain (28.57% compared to 17.72% among all the 
participants from all the clinics put together) in KaMhlushwa clinic cannot be ignored and 
needs more attention.  This is much higher than that found among a Pretoria cohort as noted 
above41.  The significantly different findings between the facilities could be a direct result of 
poor management of neuropathic pain at kaMhlushwa clinic and/or very good pain recognition 
and management at the other two clinics.   
6.5 Relationship between pain and anxiety 
Anxiety disorders were only assessed in patients who had neuropathic pain in this Nkomazi 
study. This therefore limited the analyses that could be performed. The relationship between 
Anxiety and HIV is bi-directional, thus making it difficult to determine temporality i.e. which 
came first16,52.  There was a high prevalence of anxiety disorders in this study which is 
consistent with the prevalence of psychological symptoms among PLWHIV in a multi-centre, 
Sub-Saharan Africa11.  This international sub-Saharan study used the terms worry and sadness 
in a survey designed for patient responses as being more accessible terms to describe anxiety 
and depression. Therefore, the high prevalence of anxiety disorders among the Nkomazi 
PLWHIV who experienced neuropathic pain still stands out.  Interesting the 50% of the patients 
who took part in the international study were on HAART and receiving palliative care 
concomitantly but psychological symptoms were still prominent11.  It would have been thought 
that the widespread rollout of HAART, including palliative care, would result in a reduction in 
this prevalence of anxiety disorders since patients would be expected to worry less about the 
progression of the disease, however, this has not been the case11,38.  This could be due to the 
fact that disease progression is not the only source of anxiety for patients with a chronic illness 
but the stigma and the nature of medication also increases the vulnerability to anxiety disorders.  
Our study focused on prevalence of anxiety disorders among PLWHIV who also had 
neuropathic pain, since there are more research focused on the association between depression 
and pain than there are between HIV and anxiety disorders despite the stronger association 
between HIV and anxiety10.  It is also of interest that neuropathic pain and anxiety disorders 
were comorbid in 80% of patients with neuropathic pain and it would have been of greater 
value to have sought the prevalence of anxiety disorders among those PLWHIV with non-
neuropathic pain in Nkomazi.   
45 | P a g e
Even though participants from this study were recruited at varying stages since their initiation 
of HAART, it is documented that the prevalence of Post-Traumatic Stress Disorder (PTSD) 
and anxiety increases in some PLWHIV post-diagnosis often because of an escalation of abuse 
and being stigmatised 24,28.  This was not however, explored in this study.  In this Nkomazi 
study, Panic disorders had the highest prevalence (55.56%) of all anxiety disorders (n = 72) 
which was followed by PTSD (26.39%) and Other Anxiety Disorders (9.72%).  In the literature 
reviewed the prevalence of PTSD was as high as 15-64%18.  This is a contrast to the findings 
of a previous study that was conducted in private practices of Nkomazi among non-selected 
patients where PTSD was more prevalent (29.33%) followed by Panic Disorders (24%)75. 
Participants who were interviewed from kaMhlushwa clinic were ±2.5 times more likely to be 
diagnosed with an anxiety disorder when compared to those who were seen at Naas clinic; and 
overall women in this Nkomazi study were 8% more likely to have an anxiety disorder than 
males but this was not statistically significant, a contrast to the findings by McLean et al83. 
Literature according to their article has found anxiety disorders to not only be more prevalent 
but to also be more disabling in women than in men83.   
As confirmed in this study, participants with an anxiety disorder were slightly older (median 
age of 41.5 years) than those without (Median age = 37 years).  Even though anxiety disorders 
are chronic, they are not necessarily lifelong. The median age of onset is often below the age 
of 12 years (if pre-existing)84.  The median age of onset for Panic Disorders is ± 24 years84. 
Panic disorders accounted for more than 50% of the patients with anxiety disorders, the age 
would therefore be skewed by them.  Given all this it would therefore be expected that anxiety 
disorders would be higher at an older age.   
The finding in this study that those with no education at all were more than twice more likely 
to have had an anxiety disorder than those with some primary school education is in keeping 
with those in the literature that lower educational status tended to worsen the anxiety among 
PLWHIV12,21.  This could be due to several reasons such as; an inability to negotiate for safer 
sexual practice, economic dependence, lack of knowledge and a delay to seek healthcare.  
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6.6 Prevalence of Anxiety disorders among PLWHIV in Nkomazi sub-district who also 
experience Neuropathic Pain 
Although this study did not look for anxiety disorders among non-HIV infected patients who 
attended the three clinics, it has been noted there is a strong link between anxiety and pain 
in the general population and among PLWHIV6-8.  The high prevalence (80%) of anxiety 
disorders among those Nkomazi PLWHIV confirms the reasoning that if pain in general 
increases rates of anxiety disorders among general population and among PLWHIV, then the 
prevalence of anxiety disorders among PLWHIV with neuropathic pain would be much higher. 
Panic disorders had the highest prevalence (n = 40 or 55.56%) of all anxiety disorders (n = 72) 
which was followed by PTSD (26.39% or n = 19) and Other Anxiety Disorders (n =7 or 9.72%).  
Whether, or not, this was due to escalation of abuse post-diagnosis as was the case in another 
study was not tested for in this study24,28.  This is a contrast to the findings of a previous study 
that was conducted in private practices of Nkomazi where PTSD was more prevalent (29.33%) 
followed by Panic Disorders (24%)75.  The PTSD prevalence among the Nkomazi PLWHIV 
also is in the lower range of the prevalence of PTSD among PLWHIV found in the literature 
(15-64%)18. 
6.7 Importance of Good Pain Assessment 
Without any co-morbidities neuropathic pain is already a major problem on its own; this is true 
for the sufferer, the intimate contacts and the health care providers.  It is worth noting how 
prevalent pain in general is among the Nkomazi cohort and that the prevalence of neuropathic 
pain among the PLWHIV who attended Nkomazi HIV treatment clinics is comparable to an 
urban setting in South Africa41. 
Knowing the intimate relationship between pain and anxiety disorders and seeing how 
prevalent these disorders were among the Nkomazi PLWHIV who took part in the study; there 
is good reason that routine evaluation of pain among PLWHIV pays off in the long run.  
Anxiety is known to worsen immune-suppression and pain of any kind impacts negatively on 
anxiety; so by properly managing pain in PLWHIV one would indirectly be bolstering the 
immune system of a patient in need of a robust immune system4,11,30. 
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6.8 Limitations of the study 
Despite efforts being made to enhance the study’s validity and reliability there were however 
limitations in the study. Findings cannot therefore be extrapolated outside the study setting 
(kaMhlushwa, Naas and Mangweni clinics). The study was a health facility survey that use an 
interviewer administered questionnaire: 
1. Most important of all the limitations of this study was the fact that anxiety disorders were
only assessed in patients who had neuropathic pain. This therefore limited the analyses that 
could be performed.  For instance, anxiety disorders in patients without neuropathic pain could 
have been missed.  As a result, the prevalence ratio of anxiety disorders amongst patients with 
neuropathic pain (a hypothesised exposure) and those with non-neuropathic pain (a 
hypothesized control group) could not be obtained.  Furthermore, the prevalence of anxiety 
disorders cannot be generalised to all patients living with HIV in Nkomazi sub-district but only 
to those with neuropathic pain.  
2. A healthy-worker effect bias could have been present as those who are non-symptomatic
(absence of pain, neuropathy or anxiety disorders) could have been at work or in the 
community. This could have therefore resulted in over-sampling of the “unwell”, even if all 
those PLWHIV who were sampled were presumed to have come for routine tests and collection 
of medications. 
3. The study design limited comparisons as participants all had HIV (no controls).  This study
therefore leaned towards a case-series. 
4. The environment could have been intimidating for patients and they could have therefore
given out “carefully thought out responses”.  In addition, the facilities had limited space for 
interviews, participants could have overheard responses from other respondents.  These factors 
could have therefore given rise to a social desirability bias and a diagnosis bias.  
5. The study did not make use of a validated instrument for measuring pain of all types despite
the fact that presence/absence of pain was the “entry point” in the search for neuropathic pain. 
Simply one question was asked and that was whether the patients had any nagging pain over 
the previous 4 weeks.  There could therefore be a diagnostic bias due to this.  
6. Even though the interviewers were nurses who received minimal training on the use of the
tools, an interviewer bias could have occurred as they could have brought in their personalities 
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during the interviews.  Such could have been the case when you compare the results of the pain 
prevalence of 80.77% in kaMhlushwa to those of Mangweni Clinic (10.61%). 
7. SCID-CV the instrument that was used to diagnose anxiety disorders has not been validated
and standardised for use in siSwati, the local dialect. This could have therefore affected the 
reliability of the questions and responses. 
8. The training period was significantly short period of time to adequately train non-
psychiatric nurses in the application of SCID-I (CV) for the purpose of research or in clinical 
use.  This brevity of training and recruitment of non-psychiatric nurses might have adversely 
affected the quality of data collected by these research assistants. 
9. The error of over-shooting the calculated sample size may not be seen as a limitation but a
poor supervisory role of the PI with an added advantage of the larger sample size.  
All these factors are however, balanced by the fact that all patients would have been assessed 
in the same way. 
7. CONCLUSIONS AND RECOMMENDATIONS
South Africa’s disease burden is complex and requires a systematic approach1,79. This study
aimed to determine the prevalence of common but often under-diagnosed conditions that are
often comorbid with HIV. Nkomazi Sub-district is a deprived community with a high HIV
prevalence. This study achieved its objectives by confirming a number of established findings
such as the high prevalence of pain amongst Primary Care patients living with HIV; a high
prevalence of neuropathic pain and a high prevalence of anxiety disorders among PLWHIV in
the sub-district. In addition Neuropathic pain and anxiety disorders were found to be higher in
older participants.
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1) Co-occurrence of anxiety in patients with neuropathic pain was as high as 80% which
strengthens the belief that Primary Care providers should be empowered on the management 
of pain, neuropathic disorders and anxiety disorders.  Recognition of pain of all types, but 
especially neuropathic pain should be high on the priorities of health care workers who work 
with PLWHIV. 
2) This study will serve as a baseline and yardstick for other future studies on pain in this
population. Feedback will be given to stakeholders at various levels of the community and the 
Mpumalanga department of health to get their insights on some of the outliers found in the 
study.  
3) Findings from this study will not only be shared with academics and policy makers but will
also be used as a health promotion instrument. Community participation is one of the key 
principles of health promotion. The community need to therefore be made aware of the 
importance of de-stigmatising HIV; the reduction of new HIV infections; the presence and 
treatment of anxiety disorders and various types of pain including Neuropathic pain in 
PLWHIV.  The other factors mentioned have already been part of programs of the national and 
provincial DoH, except looking at/for anxiety and pain (especially, neuropathic) in most 
patients at risk.  In this way the systematic approach to the improvement of the disease burden 
will be ensured.   
4) It would therefore be considered good clinical practice to screen for anxiety disorders in all
patients with neuropathic and non-neuropathic pain and vice-versa.  This is of course is 
dependent on time and skills level of the health care providers.  This does not mean 
administering the long and tedious SCID-CV or DN4 in all patients at all times.  Simply asking 
a follow up patient simple questions like: “are there any nagging pains, any other issues, 
worries and/or fears?”   
5) Further evaluation of the possibility of poor pain control at KaMhlushwa clinic, or that of
poor pain recognition at the other two clinics may result in additional training and a quality 
improvement programme at kaMhlushwa clinic to improve pain control or at the other two 
clinics to improve pain recognition.   
6) This study could be an eye-opener that clinicians and nurses who manage HIV treatment
centres need to have a high index of suspicion that the ‘pain’ they are treating could be 
neuropathic pain.  Even without administering the DN4 interview in full, just asking a patient 
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to describe their pain as is they were telling a friend might elicit the unique sensory descriptors 
of NeuP.  It is also important for health providers to routinely screen for pain more specifically 
in older patients, e.g. above the age of 50 as it might not always be reported82.    
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9. APPENDICES
Appendix 1: Patient Information Sheet 
Patient Information Sheet for: 
The association between Neuropathic Pain and Anxiety Disorders among patients attending HIV 
treatment centres in Nkomazi District 
1) INTRODUCTION
Thank you taking your time to hear about this study. 
You are invited to volunteer for a study.  This information leaflet is to help you to decide if you would 
like to participate.  Before you agree to take part in this study you fully understand what is involved.  
If you have any questions, which are not fully explained in this leaflet, do not hesitate to ask the 
investigator.  You should not agree to take part unless you are completely happy about all the 
procedures involved.   
2) THE NATURE AND PURPOSE OF THE STUDY
You are invited to take part in a study.  The aim of this study is to evaluate the Association between 
NEUROPATHIC PAIN (pain due to nerves in your body that are not working normally) and ANXIETY 
DISORDERS (medical conditions characterized by a feeling of dread accompanied by bodily 
symptoms and signs that cause distress, discomfort, interferes with our work/functioning and social 
life. They are not the same as fear which occurs in response to a known cause).  By doing so we wish 
to learn more about how common these medical conditions are among patients attending HIV 
treatment centres in Nkomazi district. Some illnesses could be serious and if identified early should 
save you from having problems later on. 
3) EXPLANATION OF THE PROCEDURES TO BE FOLLOWED
This study involves answering some questions with regards to your health.  There will no be physical 
examination or any tests involved. 
4) RISK AND DISCOMFORT INVOLVED
The only possible discomfort involved is sparing 25-35minutes of your time for the list of health related 
questions to be completed.  There are no procedures involved.  No experimental medicines or drugs 
shall be given. 
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5) POSSIBLE BENEFITS OF THIS STUDY. The Anxiety disorders and Neuropathic Pain are commonly
under-diagnosed and many patients suffer for years before being diagnosed.  Even when correctly
diagnosed, many patients receive inadequate treatment for these medical conditions.
There is an arrangement with your clinic to refer you for further expert help in case you are found 
to have neuropathic pain with/without an Anxiety Disorder. 
6) You should understand that if you do not want to participate in this study, you will still receive
standard treatment for your illness.
7) You may withdraw at any time from this study.
8) HAS THE STUDY RECEIVED ETHICAL APPROVAL?
This Protocol was submitted to the Faculty of Health Sciences Research Ethics Committee, University 
of Cape Town and written approval has been granted by that committee.  The study has been 
structured in accordance with the Declaration of Helsinki (last update: October2000), which deals with 
recommendations guiding doctors in biomedical research involving human subjects.  A copy of the 
Declaration may be obtained from the investigator should you wish to review it. 
Contact person at UCT Faculty of Health Sciences Human Research Committee: 
Mrs Lamees Emjedi 
Human Research Ethics Committee 
E52 Room24, Old Main Building, Groote Schuur Hospital, OBSERVATORY 
TEL: 021 406 6338 
9) INFORMATION. If you may have any questions about this study you should contact:
Dr W O Ochan Tel: 013 780 0331 Cell: 082 437 6840 
10) CONFIDENTIALITY
All records obtained whilst in this study will be regarded as confidential.  Results will be published or 
presented in such a fashion that patients remain unidentifiable. 
61 | P a g e
Appendix 2: Consent form 
CONSENT FORM FOR: 
A study of the “Association between Neuropathic pain and Anxiety disorders among patients 
attending HIV treatment centres in Nkomazi district”. 
I have read and understand the above information before signing this consent form.  The content and 
meaning of this information have been explained to me.  I have been given the opportunity to ask 
questions and am satisfied that they been answered satisfactorily.  I understand that if I do not 
participate it will not alter my treatment in any way.  I hereby volunteer to take part in this study. 
I have received a signed copy of this informed consent agreement. 
Patient:.................................................. Date:........................................ 
Person obtaining informed consent:...........................Date:........................................ 
Witness:........................................... Date:........................................ 
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VERBAL PATIENT INFORMED CONSENT 
(Applicable when patient cannot read or write) 
I, the undersigned, have read and have explained fully to the patient, 
named............................................................. and his/her relative, the patient information sheet, 
which has indicated the nature of the study in which I have asked the patient to participate.  The 
explanation I have given has mentioned both the possible risks and benefits of the study and the 
alternative treatments available for his/her illness.  The patient has indicated that he/she understands 
that he/she will be free to withdraw from the study at any time for any reason and without 
jeopardizing his/her treatment. 
I hereby certify that the patient has agreed to participate in this study. 
Patient’s Name: 
Interviewer’s Name:  ...................................... 
Interviewer’s Signature:.................................. Date:......./..../2013 
Witness’s Name: ............................................. 
Witness’s Signature:...........................................  Date:....../..../2013 
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Appendix 3: Data Collection Tools 
3.1 Demographic Data 
Instructions on how to carry to administer the Questionnaire 
->For gender identification circle F for female gender and M for the male gender. 
->Gender considered is that which is denoted on the South African barcoded green identity 
document (card) or passport. 
->In the absence of the above documents the gender considered is that which the patient 
shall report.  The appearance of the patients and their dress code shall not be used for 
identifying their gender. 
->For tribal grouping tick (1) for a Swazi, (2) for a Tsonga and (3) for other tribal or race groups. 
->Age shall be rounded off in years with no fractions or decimal points.  Eg, a participant who is 
18years and 4months shall be deemed to 18years old.  One who is 18years and seven to eleven 
months shall be deemed to be 19years old.  This shall be written next to Age…… 
->Religious affiliation shall be ticked off as (1) for Christian, (2) for Moslem, (3) Traditional 
Practitioners or (4) for others. 
->For employment status tick (1) for ‘Employed’ or (2) for ‘Not Employed’. 
->Tick (1), (2), (3) or (4) for no education, primary education, secondary education and tertiary 
education respectively. 
->For Income Levels tick (1) for no income, (2) for less than R1000, (3) for R1000-4999 or (4) for 
R5000 and over. 
Gender:  F  M 
Age:…… 
Tribal Group: Swazi (1), Tsonga (2), Other (3) 
(Nkomazi is predominantly populated by the Swazi tribal group and the Tsonga, a minority) 
Religious affiliation: (Christian (1), Moslem (2), Traditional practitioner (3), others (4)) 
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Employed? Yes (1), No (2). 
Highest Educational Achievement: None (1), Primary (2), Secondary (3), Tertiary (4) 
Income: None (1), Less than R1000/month (2), R1000-4999 (3), R5000 and above (3) 
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3.2 DN4 Interview (the sensory descriptors only) 
Instructions to Interviewer 
>Question 1 has three parts; for each of three points give one point if the symptom is present.
Each point adds up to a maximum of three points from this question. 
>Question 2 has four parts; a point is to be given for each symptom that is present up to a
maximum of four points for this question.
>The points shall be tallied out of a maximum total of 7 points, eg, 2/7 score for a patient
means that only two symptoms were found in that particular patient.
Question 1: Does the pain have any of the following characteristics? 
1.1 Burning? 
1.2 Painful sensation of cold? 
1.3 Electric shocks? 
Question 2: Is the pain associated with any of the following symptoms in the same area? 
2.1 Tingling? 
2.2 Pins and needles? 
2.3 Numbness? 
2.4 Itching? 
Tally of symptoms present:  …./7 
Eg, 3/7 means that 3 sensory descriptors of Neuropathic Pain were present. 
2/7 means that 2 sensory descriptors of Neuropathic Pain were present. 
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3.3 SCID-CV Questionnaire 
The interview shall be clinician-administered. 
Instruction to Clinician: 
>For each of the anxiety disorders there shall be a list of questions and for each there shall be
three options to choose from. 
Tick    Tick first box if information provided by the patient is not adequate/sufficient to come 
to a conclusion. 
      Tick second box if symptom sought is absent or not prominent enough. 
   Tick box third box (+)  if symptom sought is present. 
>If the (?) and (-) boxes are ticked skip the rest of the subsequent questions and proceed to
the next number. 
>If the (+) box is go then proceed step wise to the next item.
>For each anxiety disorder once the interview is completed for that section tally the number
of symptoms to see if meets, or fails to meet, the minimum number of symptoms to make a 
diagnosis is attained.  
SCID-I Score-sheet: ANXIETY/OTHER DISORDERS 
Ratings:  
    = Information not adequate. 
    = Absent (or sub-threshold).  
    = Present.  
PANIC DISORDER CRITERIA 
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If         go to F25. 
F2 (A) At least one of the following: 
(a worry about the implications of the attack. 
(b concern about having additional attacks 
(c) a significant change in behaviour
SCORE……… 
If           go to F25. 
F3 Four (or more) of the following panic attack symptoms developed abruptly and developed a peak 
within 10 minutes.       
F4 (1) palpitations 
F5 (2) sweating  
F6 (3) trembling or shaking        
F7 (4) shortness of breath        
F8 (5) choking          
F9 (6) chest pain          
F10 (7) nausea or abdominal distress 
F11 (8) feeling dizzy         
F12 (9) derealisation or depersonalization      
F13 (10) fear of losing control or going crazy 
F14 (11) fear of dying        
F15 (12) Paraesthesia’s (numbness, pins & needles) (?) 
? + - 
? - + 
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F16 (13) chills or hot flushes (?) 
F17 4/13 or more are (+) (?) ( 
SCORE….. 
If (-)   go to F25
F18 (C) Not due to a substance or medical condition (?)(-)(+) 
If there is substance abuse: go to F25.  
F19 (D) not better accounted for by another mental disorder  ( 
If there is another mental disorder go to F25 
If no other medical condition or mental disorder responsible        in F17 diagnosis = PANIC DISORDER. 
If (-)    go to F25. 
F20 (B) (1) presence of agoraphobia.  
If (-)    go to F24 
F21 (B) (2) agoraphobic situations are avoided, endured with marked distress or with anxiety, or 
requires a companion       (?)  
If         go to F24 
F22 (B) (3) the anxiety or phobic avoidance is not better accounted for by another mental disorder.
(?) 
If    go to F24 
F23 AGORAPHOBIA IS PRESNT (?) 
[  ] tick box if          on the last month... 
Diagnosis = PANIC DISORDER WITH AGORAPHOBIA if F23 is ticked 
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Go toF25 
OBSESSIVE-COMPULSIVE DISORDER CRITERIA 
F25 Obsessions 
(1)Recurrent and persistent thoughts, impulses, or images (?) 
If         go to F30 
Notes: 
F26 (2) excessive worries about real-life problems (?) 
Notes: 
If           go to F30 
F27 (3) the person attempts to ignore or suppress or neutralize such thoughts  
Notes: 
If         go F30 
F28 (4) the person recognizes that the thoughts are a product of his/her own mind 
( 
Notes: 
If         go to F30 
F29 OBSESSIONS if (1), (2), (3) and (4) are (+) 
F30Compulsions 
(1) Repetitive behaviour or mental acts (? 
Notes: 
If         go to F33 
F31 (2) the behaviour or mental acts are aimed at reducing distress (?) 
SCORE…… 
Notes: 
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F32 COMPULSIONS (1) & (2) ARE (+) (?) 
F33 EITHER F29 IS         OR F32 IS  (i.e., either obsessions or compulsions) 
(?) 
If          go F39
F34 B. The person has recognized that the obsession/compulsions are excessive or unreasonable.
(?) 
Notes: 
If           go to F39 
F35 C. The obsessions or compulsions are clinically significant  (?)  
Notes: 
If          go to F39 
F36 D. If another Axis I disorder is present, the content of the obsessions or compulsions is not 
restricted to it.        (?)  
Notes: 
If     go to F39 
F37. E. Not due to a substance or general medical condition. (?) 
Tick box [ ] if criteria met in the past month. 
If all above not due substance or medical condition DIAGNOSIS = OBSESSIVE COMPULSIVE DISORDER. 
F38 Diagnosis of OBSESSIVE-COMPULSIVE DISORDER if criteria A, B, C, D & E are  have been met 
in the past month. 
SCORE….. 
POST-TRAUMATIC STRESS DISORDER CRITERIA 
F39 TRAUMATIC EVENTS LIST 
































A) The person has been exposed to a traumatic event in which both of the following were present:
F40 (1) the person experienced, witnessed, or was confronted with an event that involved death, 
serious injury, or a threat to the physical integrity of self or others. (?) 
Note: 
If    go to F65 
F41 (2) the response involved intense fear, helplessness, or horror (?) 
Notes; 
B, The traumatic event is persistently experienced in one (or more) of the following ways: 
F42: (1) distressing recollection of the event    (?) 
Notes: 
F43:  (2) dream of the event (?) ( 
Note: 
F44: (3) acting or feeling as if the traumatic event were recurring  (?) 
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F46: (5) physiological reactivity on exposure to internal or external cues (?) ( 
SCORE…… 
F47 AT LEAST ONE ‘B’ SYMPTOM IS (+) 
If          go to F65 
C Persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness 
as indicated by three (or more) of the following: 
F48 (1) effort to avoid thoughts, feeling, or conversations related to the trauma 
(?) 
Notes: 
F49 (2) effort to avoid activities, places, or people that arouse recollections of the trauma 
(?) 
Notes:  
F50 (3) inability to recall an important to aspect of the trauma 
(?)( 
F51 (4) markedly diminished interest or participation in significant activities (?)  
Notes:  
F52 (5) feeling of detachment or estrangement from others  (?)  
Notes:  
F53 (6) restricted range of affect (e.g., not able to have loving feelings)     ( 
Notes:  
F54 (7) sense of foreshortened future       
SCORE……… 
F55 THREE OR MORE OF THE ‘C’ SYMPTOMS ARE (+) 
If           go to F65 
D Persistent symptoms of increased arousal as indicated by 2 or more of the following: 
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F57 (2) irritability or angry outbursts ( 
F58 (3) difficulty concentrating   
F59 (4) hyper-vigilance   
F60 (5) exaggerated startle response 
 
SCORE……… 
F61 TWO OR MORE ‘D’ SYMPTOMS ARE (+)  
If          go to F65 
F62 E. Duration of disturbance is more than 1month ( 
If         go to F65
F63 F. Clinically significant distress or impairment 
If         go to F65
F64 IF CRITERIA A, B, C, D, E & F ARE (+) DIAGNOSIS IS PTSD. 
Tick box [  ] if criteria have been met in past month 
OTHER ANXIETY DISORDERS 
F65 300.22 Agoraphobia without history of Panic Disorder ( 
Tick box [   ] if present in the past month 
F66 300.23 Social Phobia ( 
Tick box [  ] if present in the past month 
F67 300.29 Specific phobia (?) 
Tick box [  ] if present in the past month 
F68 300.02 Generalised Anxiety Disorder (?) 
Tick box [  ] if present in the past month 
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F69 Clinically significant anxiety or phobic avoidance  (? 
Notes:  
If          go to F72 
F70 Not due a substance or a general medical condition (?) 
If there is substance abuse or medical condition tick (-) 
If         go to F72 
If          then DIAGNOSIS IS ANXIETY DISORDER NOT OTHERWISE SPECIFIED. 
F71 Tick box [  ] if present in the past month 
SOMATOFORM DISORDERS 
F72 300.81 Somatization Disorder OR (?) 
 300.82 Undifferentiated somatoform Disorder (?) 
Notes: 
Tick box [  ] if present in the past month 
F73 300.7 Hypochondriasis (?) 
Notes: 
Tick box [ ] if present in the last month 
F74 300.7 Body Dysmorphic Disorder (?) 
Notes:  
Tick box [  ] if present in the past month 
EATING DISORDERS 
F75 307.1 Anorexia Nervosa 
Notes:  
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F76 307.51 Bulimia Nervosa (?) 
Notes: 
Tick box [  ] if present in the past month 
ADJUSTMENT DISORDERS CRITERIA 
F77 A. The development of emotional or behavioural symptoms in response to an identifiable 
stressor(s)        (?
If         end the interview.
Notes: 
F78 B. These symptoms or behaviour are clinically significant  (?) 
Notes: 
F79 C. Does not meet criteria for another specific Axis I disorder and is not an exacerbation of a pre-
existing Axis I or Axis II disorder        (?) 
Notes: 
F80 D. The symptoms do not represent Bereavement   (?)  
If bereavement tick (-) 
If          or there is bereavement stop the interview
Notes: 
F81 E. Once the stressor has terminated, the symptoms do not persist for more than extra 6months
(? 
Notes: 
If          go to D17 on the SCID-I 
If       DIAGNOSIS = ADJUSTMENT DISORDER 
F82 Make diagnosis of Adjustment Disorder based on predominant symptoms: 
Tick one: 
309.0 Adjustment Disorder with Depressed Mood (? 
309.24 Adjustment disorder with Anxiety (? 
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309.3 Adjustment Disorder with Disturbance of Conduct   (?) 
309.4 Adjustment Disorder with Mixed Disturbance of Emotions and Conduct 
309.9 Unspecified Adjustment Disorder 
End interview if F81 is (+) 
ANXIETY DISORDER DUE TO A GENERAL MEDICAL CONDITION 
F83 A. Prominent anxiety, panic attacks, obsessions, or compulsions ( 
Notes: 
F84 B/C. The disturbance is the direct physiological consequence of a general medical condition, and 
the disturbance is not better accounted for by another mental disorder  
(?) 
Notes: 
If          go to F87 
F85 E. The symptoms cause clinically significant distress or impairment (?) (- 
Notes: 
F86 CRITERIA A, B/C, AND E ARE (+) (?) 
Notes: 
If         go to F18, F37, F70 
F91 CRITERIA A, B, C & E ARE        Diagnosis = SUBSTANCE-INDUCED ANXIETY DISORDER (292.89)
 
[  ] 291.89 for Alcohol 
[  ] 292.89 for other substances 
Specify the substance................................................................................... 
Indicate type of anxiety symptoms: 
[  ] With Generalized Anxiety 
[  ] With Panic Attacks 
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[  ] With Phobic Symptoms 
Tick box [  ] if criteria have been present in the past month 
Specify the causative general medical condition: 
Indicate type of anxiety symptoms: 
[  ] With Generalized Anxiety 
[  ] With Panic Attacks 
[  ] With Obsessive-Compulsive Symptoms 
Tick box [  ] if criteria has been met in the past month 
If          go to F18, F37, F70 
If F86 is   DIAGNOSIS IS ANXIETY DISORDER DUE TO A GENERAL MEDICAL CONDITION 
SUBSTANCE-INDUCED ANXIETY DISORDER 
F87 A. Prominent anxiety, panic attacks, obsessions or compulsions  
Notes: 
If          go to F18, F37, F70
F88 B. Either: 
(1) Symptoms in A developed during/within 1 month of substance intoxication or withdrawal, or
(2) Medication use is aetiologically related to the disturbance (?) 
Notes: 
If         go to F18, F37, F70 
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Appendix 4: Permission from Clinic Heads 
4.1 Clinic 1 
The Clinic Manager 
Date.2013/03/ 14 
Dear Facility Head; 
(1)Mrs N D Ndahse
(2)Mr Victor Gwebu
RE: ASSOCIATION BETWEEN NEUROPATHIC PAIN AND ANXIETY DISORDERS AMONG 
PATIENTS ATTENDING HIV TREATMENT CENTRES IN NKOMAZI DISTRICT 
I am writing to invite your clinic to join us as a research site in this study. 
Neuropathic pain and anxiety disorders are two independents illnesses that cause untold 
suffering among people living with HIV/AIDS (PLWHA). 
These two illnesses are under-diagnosed and undertreated by doctors across the world. 
This problem of under-recognition and under-treatment by doctors is compounded by under-
reporting by PLWHA. 
This study is a cross-sectional study and there shall NOT be any experimentation with new procedures 
or medicines. 
The study instruments that shall be used during the interviews are: Demographic data, the 
DN4-Interview and the SCID-CV. 
The study shall not commence until the university and Provincial Health department has given 
ethical approval for the study. 
We shall introduce to you the research assistant, who shall have been trained in the use of 
the study instruments. 
The following are some basic pieces of the study information: 
1) Who is to be recruited for the study?
Only consenting patients on anti-retroviral therapy (ART) who are 18years, or older, shall be 
requested to participate in the study.  Two other clinics in Nkomazi district shall be 
approached to participate.  Between the 3 clinics a total of 384 patients shall be interviewed, 
approximately 126 patients form each clinic. 
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2) How will patients be approached to ask them if they would like to take part in the study?
Every 3rd patient shall be randomly approached, asked if they are interested, the study 
explained to them and recruited to participate if they give consent. 
3) How will data collection happen?
The research assistant will then interview the patient once consent has been given.  The data 
collected shall be kept in a safe case in a locked storage place.  Patients’ names and identifying 
characteristics shall not be recorded.  The questionnaires shall only have a number which is 
not unique to the patient. 
4) What is a patient becomes distressed?
Every participant has the opportunity to stop the interview at any time and may be given time 
at end of interview to talk without any data being recorded.  The clinic sisters shall also be 
informed of such a patient as well. 
5) Responsibilities of the study site (the clinic) are the following:
-Introducing the research assistant to the patients.
-Introduction of the other clinic personnel to the research assistant, and vice-versa.
-Ensuring patients that shall participate in the study not miss out laboratory tests and
medication supplies.
6) Study feedback.
The research assistant shall give frequent progress report about study.  When the study is 
concluded a copy of the results in lay terminology shall be displayed at the clinic. 
We look forward to working with your clinic and clients. 
For more information do not hesitate to contact us as, and when, the need arises. 
Sincerely yours; 
Dr Walter O Ochan 
mwochan@mweb.co.za 
painmed.ochan@gmail.com 
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4.2 Clinic 2 
The Clinic Manager 
Date.2013/03/ 14 
Dear Facility Head; 
(1)Mrs N D Ndahse
(2)Mr Victor Gwebu
RE: ASSOCIATION BETWEEN NEUROPATHIC PAIN AND ANXIETY DISORDERS AMONG 
PATIENTS ATTENDING HIV TREATMENT CENTRES IN NKOMAZI DISTRICT 
I am writing to invite your clinic to join us as a research site in this study. 
Neuropathic pain and anxiety disorders are two independents illnesses that cause untold 
suffering among people living with HIV/AIDS (PLWHA). 
These two illnesses are under-diagnosed and undertreated by doctors across the world. 
This problem of under-recognition and under-treatment by doctors is compounded by under-
reporting by PLWHA. 
This study is a cross-sectional study and there shall NOT be an experimentation with new 
procedures or medicines. 
The study instruments that shall be used during the interviews are: Demographic data, the 
DN4-Interview and the SCID-CV. 
The study shall not commence until the university and Provincial Health department has given 
ethical approval for the study. 
We shall introduce to you the research assistant, who shall have been trained in the use of 
the study instruments. 
The following are some basic pieces of the study information: 
1) Who is to be recruited for the study?
Only consenting patients on anti-retroviral therapy (ART) who are 18years, or older, shall be 
requested to participate in the study.  Two other clinics in Nkomazi district shall be 
approached to participate.  Between the 3 clinics a total of 384 patients shall be interviewed, 
approximately 126 patients form each clinic. 
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2) How will patients be approached to ask them if they would like to take part in the study?
Every 3rd patient shall be randomly approached, asked if they are interested, the study 
explained to them and recruited to participate if they give consent. 
3) How will data collection happen?
The research assistant will then interview the patient once consent has been given.  The data 
collected shall be kept in a safe case in a locked storage place.  Patients’ names and identifying 
characteristics shall not be recorded.  The questionnaires shall only have a number which is 
not unique to the patient. 
4) What is a patient becomes distressed?
Every participant has the opportunity to stop the interview at any time and may be given time 
at end of interview to talk without any data being recorded.  The clinic sisters shall also be 
informed of such a patient as well. 
5) Responsibilities of the study site (the clinic) are the following:
-Introducing the research assistant to the patients.
-Introduction of the other clinic personnel to the research assistant, and vice-versa.
-Ensuring patients that shall participate in the study not miss out laboratory tests and
medication supplies.
6) Study feedback.
The research assistant shall give frequent progress report about study.  When the study is 
concluded a copy of the results in lay terminology shall be displayed at the clinic. 
We look forward to working with your clinic and clients. 
For more information do not hesitate to contact us as, and when, the need arises. 
Sincerely yours; 
Dr Walter O Ochan 
mwochan@mweb.co.za 
painmed.ochan@gmail.com 
83 | P a g e
84 | P a g e
Appendix 5: University of Cape Town HREC Approval 
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Appendix 5: Mpumalanga Provincial Ethics Approval 
